# CAR-TCR

## Engineering A Disease-Free World

**September 19-22, 2022** | Boston, MA

In Proud Partnership with:

emily whitehead foundation
activate the cure for childhood cancer

Use the interactive menu on the right to quickly navigate the agenda!

## Develop & Deliver at Scale Life-Changing CAR-T & TCR Cell Therapies that are Safe & Effective from Vein-to-Vein

**Helen Tayton-Martin**
Chief Business Officer
**Adaptimmune**

**Francesco Galimi**
Chief Medical Officer
**Adicet Bio**

**Adrian Bot**
Chief Scientific Officer
**Capstan Therapeutics**

**Lynelle Hoch**
Senior Vice President
**Bristol Myers Squibb**

**Vipin Suri**
Chief Scientific Officer
**Catamaran Bio**

**Luis Borges**
Chief Scientific Officer
**Century Therapeutics**

**Bob Valamehr**
Chief Research & Development Officer
**Fate Therapeutics**

**Karen Walker**
Chief Technical Officer
**Kyverna Therapeutics**

**Christina Coughlin**
Chief Executive Officer
**Cytoimmune Therapeutics**

**Lead Partner:**

Lonza

**Expertise Partners:**

ALLCELLS A Discovery Life Sciences™ Company
EVERSANA
PRECISION ADVANCE the cell & gene therapy collective™
TERUMO BLOOD AND CELL TECHNOLOGIES
ThermoFisher SCIENTIFIC



REGISTER BY SEPTEMBER 18 TO SAVE $150



REGISTER NOW

# Contents

The most anticipated event of the cell therapy calendar, the **7th CAR-TCR Summit**, is back in Boston with a bang! This is your one stop shop for all your CAR and TCR cell immunotherapy needs. Join the global community across 4 days and 8 tracks as we explore discovery through to commercialization to deliver safe, effective and commercially viable CAR and TCR therapies.



# 2022 Agenda Highlights

September 19-22, 2022
Boston, MA

CAR-TCR

## DISCOVERY

- Optimize *in vivo* reprogramming for enhanced control
- Drive identification and validation of novel targets to achieve success in solid tumors
- Develop armored approaches to increase persistence and resilience

## TRANSLATION

- Drive development of validated biomarker strategies to improve translational success
- Explore novel preclinical models to drive and direct clinical trial development
- Infiltrate the hostile tumor microenvironment to improve persistency and durability

## CLINICAL MANAGEMENT

- Optimize management of high-risk patients to improve therapeutic journey
- Maximize clinical outcomes with RNA based approaches
- Delve into applications of adjuvants to enhance performance of current CAR-T therapies

## EARLY PHASE DEVELOPMENT

- Dive into case studies showcasing how to ensure clinical trial readiness
- Meet wider patient populations with bespoke education and training programs
- Enter the clinic with operational readiness

## MANUFACTURING

- Use automation to reduce manufacturing complexity and optimize scalability
- Achieve transient CAR expression using non-viral gene modification strategies
- Explore innovation in viral vector production for optimized process development

## CMC/ANALYTICS

- Streamline CMC workflow to achieve faster release
- Drive reproducibility for a high-quality product
- Establish gold standards for potency testing to inform downstream product design

## LOGISTICS

- Establish industry-wide guidelines for complex cell therapy supply chains
- Ensure secure movement across the entire supply chain using universal and traceable systems
- Develop an end-to-end integrated workflow for autologous and allogeneic cell products

## MARKET ACCESS

- Overcome solid tumor challenges
- Advance novel construct design for *in vivo* and allogeneic cell therapies
- Develop logic-gated and multi-targeted approaches to supercharge cell therapies

REGISTER BY SEPTEMBER 18 TO SAVE $150



REGISTER NOW

# Welcome to the 7th CAR-TCR Summit

## A Letter from our Program Director

### To Our Global CAR-TCR Community,

This year, the cell immunotherapy field has reached the remarkable point at which CAR-T therapies can be considered curative.

Now the long-standing commercial CAR-T players must unite with the hottest trailblazing industry pioneers to shape and secure the future of cell therapy.

That's why the **7th CAR-TCR Summit** returns to Boston in 2022 bigger and back in person as the world's pre-eminent industry-leading comprehensive forum with one goal: to engineer a disease-free world.

Across **4 days** of carefully curated sessions, we will gather with **200+ CAR** and **TCR cell therapy VIPs** that will lead you and your peers in discussions from novel allogeneic approaches with enhanced safety considerations, the latest ***in vivo* gene engineering techniques**, and advances in **CMC strategies** and **analytical development** to ensure development of high-quality cell products.

With the crème de la crème of cell therapy development coming together at the CAR-TCR Summit to discuss leveraging the powerful potential of **combined modalities**, back translation to learn from our successes and pitfalls, and **manufacturing automation** innovations for large scale consistent production, you can't afford to miss the **7th CAR-TCR Summit** as we bring you more speakers, more content and more exclusive insights than ever before!

I look forward to welcoming you to Boston this September to herald in a new frontier of medical marvels that can really cure the uncurable.

Rochelle Allen
Senior Program Director – CAR-TCR Series
Hanson Wade

## 5 Reasons Why This is Your Must-Attend Meeting of the Year:

- Discover the latest *in vivo* gene engineering techniques to improve safety, tolerability and efficacy for complex cell therapies with **Capstan Therapeutics**, **Mustang Bio**, **ImmTune Therapies** and **Umoja Biopharma**
- Uncover the blockbuster potential of combining modalities by leveraging the power of CAR technology across T-cells, NK cells, iPSC and macrophages with **Notch Therapeutics**, **Carisma Therapeutics**, **Catamaran Bio**, **Fate Therapeutics** and more!
- Elevate your CMC and analytical workstreams with **Vor Biopharma**, **Triumvira Immunologics**, **Kyverna Therapeutics** and **Adicet Bio** to optimize development of safe and high-quality cell products
- Achieve success during early phase 1/2 development as seasoned industry experts from the likes of **T-Knife Therapeutics**, **Bristol Myers Squibb**, **IN8bio** and **Immatics** showcase how to seamlessly scale up and build phase appropriate infrastructure
- Expedite development of commercially viable therapies with **Gilead**, **Chimeric Therapeutics**, **Autolus** and **Takeda** as they explore novel pricing and reimbursement models and explore how to prepare for commercial readiness right from product conception



REGISTER NOW

# Key Talks You Cannot Miss:

***In Vivo* Generation of Functionally Active CAR-T Cells**

**Bakul Gupta**, Chief Executive Officer, **ImmTune Therapies**

**RNA Cell Therapies: The Benefits of Being Tame & Temporary**

**Michael Singer**, Chief Scientific Officer, **Cartesian Therapeutics**

**Showcasing the Journey to Developing a Market Ready Strategy**

**Lynelle Hoch**, Senior Vice President, Cell Therapy Franchise Lead, **Bristol Myers Squibb**

**Industrialization of CAR-T Therapies Autologous vs Allogeneic: Common & Uncommon Hurdles**

**Karen Walker**, Chief Technology Officer, **Kyverna Therapeutics**

**Teaching an Elephant to Surf - Overcoming Big Pharma Cell & Gene Therapy Industrialization Challenges for Value Chain Orchestration & Exceptions Management**

**Christian Fuchs**, Head of Orchestration & Exceptions Management Cell & Gene Therapy, **Roche/Genentech**

## Industry Partners:

A2 BIO

SERVIER

# What's New for 2022?

September 19-22, 2022
Boston, MA

CAR-TCR

NEW DATA RELEASED

**New Companies:**

Gain access to talks from new companies that have NEVER spoken at the CAR-TCR Summit before such as **Currus Biologics**, **ImmTune Therapies**, **Rootpath**, **Strand Therapeutics**, **Deverra Therapeutics** and more as they shake up the industry with new cutting-edge platforms and disruptive technologies.

3 DAYS

**3 Main Conference Days:**

As the cell therapy space continues to explode with new companies and more data being generated at a rapid pace, we are keeping up with this growth by adding in an additional **THIRD main conference day** to ensure the full landscape is captured so you can stay ahead of the curve!

**New CMC/ Analytics Track**

A very popular new addition to the program – the brand-new track dedicated to CMC and **analytical innovations** that are paving the way for greater understanding and characterization of cell products to best showcase quality, safety and potency.

**CAR-TCR Think Tank**

The all-new CAR-TCR Think Tank is an exclusive invite-only session, with top C-Level Executives gathering to share thought leadership on how to drive the cell therapy field into a new era of more accessible 'curative' therapies.

**Investors Roundtable:**

Gathering expert **venture capitalists**, **business angels** and **corporate venture funds**, this is an exclusive opportunity to gain insights into the current priorities of investors and how to **set your company apart** to raise financing and secure reliable streams of capital.

REGISTER BY SEPTEMBER 18 TO SAVE $150



REGISTER NOW

# Expert Speaker Faculty



**Leah Sibener**
Co-Founder,
Vice President of
Therapeutic Discovery
**3T Biosciences**

**Cory Bentley**
Co-Founder, Senior
Vice President
**Abintus Bio**

**Nicholas Boyle**
Co-Founder, Chief
Executive Officer
**Abintus Bio**

**Teng Peng**
Senior Technique
Application Manager
**ACRO Biosystems,Inc.**

**Helen Tayton-Martin**
Chief Business Officer
**Adaptimmune**

**Erik Yusko**
Senior Director, Drug
Discovery
**Adaptive
Biotechnologies**

**Francesco Galimi**
Chief Medical Officer
**Adicet Bio**

**Anthony Colenburg**
Director of Quality
**Adicet Bio**

**Damien Hallet**
Vice President, Head
of CMC
**Affini-T Therapeutics**

**Eric Von Hofe**
Senior Advisor
**AffyImmune**

**Giuliana Vallanti**
Head, Development
and Global Cell &Gene
Therapy R&D
**AGC Biologics**

**Robert Margolin**
Vice President
of Commercial,
BioProducts Business
**Akron Bio**

**Paul Rennert**
Acting Chief Executive
Officer, President,
Chief Scientific Officer
**Aleta
Biotherapeutics**

**Dominic Clarke**
Chief Technical Officer,
Cell & Gene Therapy
**AllCells, A Discovery
Life Sciences
Company**

**Erin Karski**
Executive Director
**Allogene
Therapeutics**

**Nicole Hilgraf**
Director, CMC
Regulatory Affairs
**Allogene**

**Melissa Sebok**
Executive Director –
Product, Client & Business
Development, Direct Patient
Care & Emerging Offerings
**American Red Cross
Biomedical Services**

**Lung-I Cheng**
Vice President, Cell
and Gene Therapy
**AmerisourceBergen**

**Luke Pase**
Chief Technology
Officer
**Anocca**

**Reagan Jarvis**
Co-Founder & Chief
Executive Officer
**Anocca**

**Sven Kili**
Chief Executive Officer
**Antion Biosciences**

# Expert Speaker Faculty



**David Kim**
Head of Supply Chain
**Arcellx**



**Aaron Cooper**
Senior Director of Synthetic Biology
**ArsenalBio**

**Jodie Wehling**
Vice President, Market Access, Payer Marketing & Strategic Accounts
**Atara Biotherapeutics**

**Pascal Touchon**
President, Chief Executive Officer
**Atara Biotherapeutics**

**Zhimei Du**
Vice President of Process Development
**Atara Biotherapeutics**

**Brent Rice**
Senior Vice President, Chief Commercial Officer
**Autolus**

**William Shingler**
Senior Director, Patient and Cell Management
**Autolus**

**Bertie MacArthur**
Sales Manager
**Beacon Targeted Therapies**

**Sophia Shamsi**
Lead Analyst
**Beacon Targeted Therapies**

**Brad Hartman**
Chief People Officer
**Be Biopharma**

**Joy Aho**
Director, Product Management
**Be The Match BioTherapies**

**Ellie Kamaloo**
Senior Scientist, Manager
**Beam Therapeutics**

**Melissa Le**
Scientist
**Beam Therapeutics**

**Alpana Kumari**
Business Development Manager
**Advanced Cell Diagnostics, a Bio-Techne Brand**



**David Hermanson**
Senior Manager of R&D Applications, Cell and Gene Therapy
**Bio-Techne**



**Charles Mooney**
Vice President, Bio-Development Oklahoma Blood Institute
**Blood Centers of America & BCA CT Network**

**Anne Kerber**
Senior Vice President
**Bristol Myers Squibb**

**Lynelle Hoch**
Senior Vice President
**Bristol Myers Squibb**

**Elena Peletskaya**
Senior Scientific Director, GDE Portfolio Technical Strategy
**Bristol Myers Squibb**

**Ivie Aifuwa**
Associate Director, Process Technology Development
**Bristol Myers Squibb**

**Tracy Turner**
Scientist, Formulation and Cryobiology in the Cell Therapy Development Organization
**Bristol Myers Squibb**

# Expert Speaker Faculty



**Samik Basu**
Chief Scientific Officer
**Cabaletta Bio**

**Travis Young**
Vice President Biologics
**Calibr at Scripps Research**

**Ashish Kothari**
Vice President - Cell Transplant Therapy
**CareDx**

**Kent Amsberyy**
Director, Advanced Therapy Product Development Regulatory Sciences, Specialty Solutions
**Cardinal Health**

**Justin Skoble**
Vice President, Technical Operations
**Caribou Biosciences**

**Syed Rizvi**
Chief Medical Officer
**Caribou Biosciences**

**Michael Klichinsky**
Chief Scientific Officer & Co-Founder
**Carisma Therapeutics**

**Hong Ma**
Senior Vice President - Clinical Development
**CARsgen Therapeutics**

**Michael Singer**
Chief Scientific Officer
**Cartesian Therapeutics**

**Miloš Miljković**
Chief Medical Officer
**Cartesian Therapeutics**

**Adrian Bot**
Chief Scientific Officer & Executive Vice President
**Capstan Therapeutics**

**Haig Aghajanian**
Vice President of Research
**Capstan Therapeutics**

**Michael DeRidder**
Senior Vice President Corporate Strategy & New Product Planning
**Catamaran Bio**

**Joseph Gold**
Vice President of Technical Operations & Manufacturing
**Catamaran Bio**

**Vipin Suri**
Chief Scientific Officer
**Catamaran Bio**

**Fabian Gerlinghaus**
Co-Founder, Chief Executive Officer
**Cellares**

**Kathryn Newhall**
Vice President, Head of Translational Research
**Cellectis**

**Arthur Stril**
Chief Business Officer
**Cellectis**

**Bradley Glover**
Chief Technology Officer
**Celularity**

**John Lee**
Vice President of Cell Therapy
**Center for Breakthrough Medicines**

**Jeet Sarkar**
Vice President, Information Technology
**Center for Breakthrough Medicines**

# Expert Speaker Faculty



**Luis Borges**
Chief Scientific Officer
**Century Therapeutics**

**Hy Levitsky**
President, Research & Development
**Century Therapeutics**

**Indu Ramachandran**
Head of Translational Development
**Century Therapeutics**

**Damien Fink**
Director of Analytical Development
**Century Therapeutics**

**John Rossi**
Vice President, Head of Translational Medicine
**Syncopation Life Sciences**

**Daniel Corey**
Chief Scientific Officer
**CERo Therapeutics, Inc**

**Ankita Das**
Senior Product Manager, RNA/DNA
**Codex DNA**

**Tony Ho**
Industry Expert
Self Employed,
Previously
**CRISPR Therapeutics**

**Matthew Hewitt**
Executive Director - Scientific Solutions, Cell & Gene Therapy
**Charles River Laboratories**

**Gemma Moiset**
Group Leader
**Charles River Laboratories**

**Nick Ostrout**
Senior Scientific Advisor
**Charles River Laboratories**

**Jennifer Chow**
Chief Executive Officer, Managing Director
**Chimeric Therapeutics**

**Lior Goldberg**
Pediatric Oncologist, Physician-Scientist
**City of Hope Comprehensive Cancer Center**

**Mark Sawicki**
President & Chief Executive Officer
**Cryoport**

**Sam Cobb**
Chief Executive Officer
**Currus Biologics**

**Christina Coughlin**
Chief Executive Officer
**Cytoimmune Therapeutics**

**Stanley Frankel**
Chief Medical Officer
**Cytovia Therapeutics**

Dana-Farber Cancer Institute

**Zankar Desai**
Cell Therapy Testing Lab Manager
**Dana-Farber Cancer Institute**

**Rizwan Romee**
Associate Professor of Medicine
**Dana Farber Cancer Institute, Harvard Medical School**

**Erika von Euw**
Vice President, Discovery & Translational Research
**Devarra Therapeutics**

**Colleen Delaney**
Founder & Chief Scientific Officer, Executive Vice President of Research & Development
**Deverra Therapeutics**

# Expert Speaker Faculty





**Jenna Balestrini**
Head of Strategy and Business Development for Bioprocessing
**Draper**



**Tom Whitehead**
Co-founder
**Emily Whitehead Foundation**

**Cheng Liu**
Founder, Chief Executive Officer
**Eureka Therapeutics**

**Maria Kirsch**
General Manager, Patient Services
**EVERSANA**

**Seth Gordon**
General Manager
**EVERSANA™ ENGAGE**

**Gregory Fiore**
Chief Executive Officer
**Exacis Biotherapeutics**

**Hanna Lesch**
Chief Technology Officer
**Exothera**

**Raedun Clarke**
Senior Director, Process Development
**Fate Therapeutics**

**Bob Valamehr**
Chief Research & Development Officer
**Fate Therapeutics**

**Yu-Waye Chu**
Chief Medical Officer
**Fate Therapeutics**

**Sylvain Simon**
Postdoctoral Fellow
**Fred Hutchinson Cancer Research Center**

**Mark Throsby**
Chief Operating Officer, Chief Scientific Officer
**Gadeta**

**Karen Wen**
Chief Operating Officer
**GenomeFrontier Therapeutics, Inc.**

**Sareina Wu**
Founder, Chief Scientific Officer
**Genome Frontier**

**Michelle Andraza**
Senior Director, Global Quality Assurance
**Exuma Biotech**

**Sid Kerkar**
Vice President, Head of Research & Development
**Exuma Biotechnology**

**Laura Okpala**
Senior Director, Reimbursement Policy
**Gilead Sciences**

**Chris Baldwin**
Senior Director, Cell & Gene Therapy Supply Chain
**GSK**

**Ellie Corigliano**
Head of CDx Cell & Gene Therapy, Global Clinical Development
**GSK**

**Daniel Abate-Daga**
Associate Professor
**H. Lee Moffitt Cancer Center & Research Institute & University of South Florida**

horizon
a PerkinElmer company

**Branden Smeester**
R&D Scientist
**Horizon Discovery**

# Expert Speaker Faculty



**Jim Wise**
Vice President, Head of Center for Immuno-Oncology, Cellular & Gene Therapy
**ICON Global Operations**

**Michael Mehler**
Director, Global Site Operations
**Immatics**

**Jim Johnston**
Chief Scientific Officer
**ImmPACT Bio**

**Bakul Gupta**
Chief Executive Officer
**ImmTune Therapies**

**Dan MacLeod**
Vice President, Discovery
**ImmunoScape**

**Kate Rochlin**
Chief Operating Officer
**IN8bio**

**Lucy Lu**
Chief Operating Officer
**Innovative Cellular Therapeutics**

**Zachary Roberts**
Chief Medical Officer
**Instil Bio, Inc**

**Michael Phelan**
Application Scientist
**Integral Molecular**

**Birgit Schultes**
Senior Vice President, Head of Cell Therapies
**Intellia**

**Sumit Verma**
Senior Vice President, Commercial Operations
**Iovance Biotherapeutics**

**Madan Jagasia**
Senior Vice President Medical Affairs
**Iovance Biotherapeutics**

**Parameswaran Hari**
Senior Vice President Clinical Sciences
**Iovance Biotherapeutics**

**Arvind Natarajan**
Senior Vice President, Process & Analytical Process Development
**Iovance Biotherapeutics**

**Jason Collins**
Director of Process Architecture
**IPS**

**George Todorov**
Senior Process Engineer
**IPS**

**Sean Mackay**
Chief Executive Officer & Founder
**IsoPlexis**

**Warner Biddle**
SVP & Global Head of Commercial
**Kite Pharma**

**Qi Cai**
Director of Biology
**Kite Pharma**

**Judith Koliwer**
Principal Consultant Cell & Gene Therapy
**Körber Pharma Software**

**James Chung**
Chief Medical Officer
**Kyverna Therapeutics**



REGISTER BY SEPTEMBER 18 TO SAVE $150

CONTENTS
WELCOME
WHAT'S NEW FOR 2022
SPEAKERS
AGENDA AT A GLANCE
DEEP DIVE DAY WORKSHOPS
DEEP DIVE DAY BOOTCAMPS
FOCUS DAY
DISCOVERY TRACK
TRANSLATION TRACK
CLINICAL MANAGEMENT TRACK
EARLY PHASE DEVELOPMENT TRACK
MANUFACTURING TRACK
CMC/ANALYTICS TRACK
LOGISTICS TRACK
MARKET ACCESS TRACK
PARTNERS
WHO WILL YOU MEET
PRICING & DISCOUNTS

REGISTER NOW

# Expert Speaker Faculty



**Karen Walker**
Chief Technology Officer
**Kyverna Therapeutics**

**Taylor Jensen**
Vice President, Head of Oncology Science
**Labcorp**

**Steve Gavel**
Vice President Global Commercial Development
**Legend Biotech**



**Marc Davies**
Vice President, CAR Engineering
**Leucid Bio**

**Tamara Laskowski**
Head of Clinical Development Personalized Medicine
**Lonza**

**Joseph Garrity**
Head of Commercial Development Cell & Gene Therapies
**Lonza**

**Will Singleterry**
Commercial Director, Immuno-Oncology
**LUMICKS**

**Gary Lee**
Chief Scientific Officer
**Lyell Immunopharma**

**Michael Birnbaum**
Associate Professor, Department of Biological Engineering
**Massachusetts Institute of Technology**

**Tristan Holland**
Laboratory Head, TCR Discovery
**Medigene**

**Hiroshi Shiku**
Professor
**Mie University Graduate School of Medicine**

**Isabelle Riviere**
Director, Cell Therapy & Cell Engineering Laboratory
**Memorial Sloan Kettering Cancer Center**

**Katsuhiko Nakashima**
Associate Director, MSAT
**Minaris**

**Marc van Dijk**
Chief Scientific Officer
**MiNK Therapeutics**

**Christopher Wiwi**
Vice President, Technical Operations
**Mnemo Therapeutics**

**Kumar Karyampudi**
Director, Cell Therapies Facility
**Moffitt Cancer Center**

**Knut Niss**
Chief Technology Officer
**Mustang Bio**

**Ed Armstrong**
Senior Director, Quality
**Mustang Bio**

**Lili Wang**
Senior Research Scientist
**National Institute of Standards & Technology**

**Mark Trusheim**
Strategic Director
**Massachusetts Institute of Technology, NEWDIGS**

**Emily Titus**
Vice President
**Notch Therapeutics**

# Expert Speaker Faculty



**Christopher Bond**
Vice President Preclinical & Translational Sciences
**Notch Therapeutics**

**Antoine Suteau**
Senior Quality Assurance Manager, Cell & Gene Therapy
**Novartis**

**Oliver Eitelwein**
Partner, Health & Life Sciences
**Oliver Wyman**

**William Kelce**
Executive Director & Early Development Strategy
**OncoBay Clinical**

**Dannelle Palmer**
Chief Operating Officer
**OncoBay Clinical**

**Michael O'Dwyer**
Chief Scientific Officer
**ONK Therapeutics**

**Jason Foster**
Chief Executive Officer
**Ori Biotech**

**Robert Mabry**
Chief Scientific Officer
**Orna Therapeutics**

**Devon Shedlock**
Chief Scientific Officer
**Poseida Therapeutics**

**Aish Sathyanarayan**
Senior Scientist, Process Analytics
**Poseida Therapeutics**

**Stacey Cranert**
Director of Immuno-Oncology
**Poseida Therapeutics**

**Bob Amareld**
Head of Supply Chain
**Precision Biosciences**

**Ryan Phillips**
Strategic Sourcing Manager
**Precision Biosciences**

**Justin Denlevy**
Clinical Supply Chain Manager
**Precision Biosciences**

**Angela Zhang**
Senior Product Manager
**Precision Nanosystems**

**Daniel Shelly**
Vice President Business Development & Alliances
**Prescient Therapeutics**

**Rebecca Lim**
Vice President, Scientific Affairs
**Prescient Therapeutics**

**John Khoury**
EVP
**Project Farma**

**Vita Golubovskaya**
Senior Director, Research & Development, Business Development
**ProMab Biotechnologies**

**Julia Gilden**
Senior Scientist
**Promega**

**Brian Champion**
Chief Scientific Officer
**PsiOxus Therapeutics**

# Expert Speaker Faculty



**Kent Thorup**
Regional Vice President
**QuickSTAT Global Life Science Logistics**

**Christian Fuchs**
Head of Orchestration & Exceptions Management, Cell & Gene Therapy
**Roche/ Genentech**

**Ely Porter**
Co-founder, Chief Technology Officer
**Rootpath**

**Marty Giedlin**
Vice President, Head of Technical Operations
**Senti Bio**

**Wenzhong Guo**
Chief Technology Officer, Cell Therapy
**Sorrento Therapeutics**

**Geofrey Hodge**
Chief Executive Officer
**SOTIO Biotech**

**Amy Jensen-Smith**
Senior Director, Head of Discovery Research
**SOTIO Biotech**

**Jacob Becraft**
Co-Founder, Chief Executive Officer
**Strand Therapeutics**

**Gaurav Narula**
Professor Pediatric Oncology & Health Sciences, Department of Medical Oncology
**Tata Memorial Center, Homi Bhabha National Institute**

**Albeena Nisar**
Scientific Officer, CAR-T Cell Therapy Centre & cGMP Cell Therapy Centre,
**Tata Memorial Center, Homi Bhabha National Institute**

**Michael Leek**
Executive Chairman and Founder
**TC BioPharm**

**Peter Olagunju**
Chief Technology Officer
**TCR² Therapeutics**

**Aaron Vernon**
Vice President, Technical Operations
**TCR² Therapeutics**

**Angela Justice**
Chief People Officer
**TCR² Therapeutics**

**Wenyan Leong**
Senior Marketing Manager, Cell Therapy Solutions
**Terumo Blood and Cell Technology**

**Jens Hasskarl**
Chief Medical Officer
**Tigen Pharma**

**Harb Wael**
Vice President Medical Affairs
**Syneos Health**

**Rebecca Nugent**
Vice President, Platform Research
**Synthego**

**Candice Lo**
Global Value & Access Lead, Cell Therapies
**Takeda Oncology**

**Shirley Bartido**
Director, Global Regulatory Affairs Cell Therapy Oncology
**Takeda Pharmaceutical Company**

**Lan Cao**
Vice President, Head of Cell Therapy Innovation
**Takeda Oncology**

# Expert Speaker Faculty



**Michael Lehmicke**
Vice President, Science & Industry Affairs
**The Alliance for Regenerative Medicine**

**James Keck**
Senior Director of Innovation & Product Development
**The Jackson Laboratory**

**Susan Li**
Director of Customer Solutions, BioServices & Specialty Logistics
**Thermo Fisher Scientific**

**Xavier de Mollerat du Jeu**
Senior Director of Research & Development
**Thermo Fisher Scientific**

**Evan Zynda**
Senior Staff Scientist, Cell Biology
**Thermo Fisher Scientific**

**Youngzee Song**
R&D Manager
**Thermo Fisher Scientific**

**Elisa Kieback**
Co-Founder, Chief Technology Officer
**T-Knife Therapeutics**

**Michael Marit**
Associate Director, MSAT
**Triumvira Immunologics**



**Deyaa Adib**
Chief Medical Officer
**Triumvira Immunologics Inc.**

**Arnaud Deladeriere**
Director of Process Development
**Triumvira Immunologics Inc.**

**Steven Katz**
Chief Medical Officer
**TriSalus Life Sciences**

**Blythe Sather**
Vice President, Head of Research
**Tune Therapeutics**

**Aaron Sato**
Chief Scientific Officer
**Twist Bioscience**

**Scott Kitchen**
Professor, Director
**University of California, Los Angeles**



**David Fontana**
Chief Business & Strategy Officer
**Umoja Biopharma**

**Muneesh Tewari**
Professor of Internal Medicine and Biomedical Engineering, Anderson-Sprague Memorial Research Professor
**University of Michigan**

**Daniel Powell**
Associate Professor of Pathology & Lab Medicine
**University of Pennsylvania**

**Neil Sheppard**
Director T-Cell Engineering Lab
**University of Pennsylvania**

**Robert Richards**
Administrative Director of Cell Therapy & Transplant
**University of Pennsylvania**



**Bruce Levine**
Barbara & Edward Netter Professor in Cancer Gene Therapy
**University of Pennsylvania**

**Marko Radic**
Associate Professor of Microbiology, Immunology & Biochemistry
**University of Tennessee Health Science Center**

# Expert Speaker Faculty

**Archana Thakur**
Associate Professor of Medicine, Director of Human Cellular Therapeutics cGMP Core
**University of Virginia, School of Medicine**

**Andrea Zobel**
Senior Director, Personalized Supply Chain
**World Courier**

**Sankalp Sethi**
Principal – Cell and Gene Therapy
**ZS**

**Maria Whitman**
Global Head of Pharmaceuticals & Biotechnology
**ZS**

"This conference sets the gold standard for bringing people in the industry together to collaborate and inspires them"

**Co-Founder, Emily Whitehead Foundation**

"Amazing selection of speakers from both academia and industry working together to bring more cellular therapies to patients that need them"

**Astellas Pharma**

# 7th CAR-TCR Summit - Agenda at a Glance

September 19-22, 2022
Boston, MA

CAR-TCR





## Pre-Conference Workshop Day
Monday, September 19

*Opening Remarks*

WS | WS | WS | WS | WS | 101 | FD1 | FD2 | FD3

*Networking*

WS | WS | WS | WS | WS | 101 | FD1 | FD2 | FD3

*Lunch*

WS | WS | WS | WS | WS | 101 | FD1 | FD2 | FD3

*Afternoon Refreshments*

**Investors Pitch**

**CEO Think Tank**

**Diversity Roundtables**

**Ambassador's Reception**

## Conference Day 1
Tuesday, September 20

*Opening Remarks*

**Industry Leaders Fireside Chat**

*Networking*

A | B | C | D | E | F | G | H

*Lunch*

A | B | C | D | E | F | G | H

**Tech Slam**

A | B | C | D | E | F | G | H

*Drinks Reception*

## Conference Day 2
Wednesday, September 21

*Opening Remarks*

**Late Breaking Abstracts**

*Tech Slam*

A | B | C | D | E | F | G | H

*Lunch*

A | B | C | D | E | F | G | H

**Networking**

A | B | C | D | E | F | G | H

*Poster Session*

*Close of Day 2*

## Conference Day 3
Thursday, September 22

NEW

*Opening Remarks*

**Next Generation Leaders Fireside Chat**

**Tech Slam**

A | B | C | D | E | F | G | H

*Lunch & Poster Session*

A | B | C | D | E | F | G | H

**Afternoon Plenary**

*Close of Day 3*

| A – Discovery | B – Translational | C – Clinical Management | D – Early Phase Development | E – Manufacturing | F – CMC/Analytics NEW FOR 2022! | G – Logistics | H – Market Access |
|---|---|---|---|---|---|---|---|



hansonwade

**7.00 Networking**

## Workshop A

**8.00 Improving TCR-Target Interactions to Enhance Persistence *In Vivo***

- Characterizing TCRs and defining what makes a good TCR
- Developing high quality TCRs to optimize stringency and potency without minimizing target specificity
- Enhancing the potency of TCRs – challenges, risks and potential

**Reagan Jarvis**, Co-Founder & Chief Executive Officer, **Anocca**

## Workshop B

**8.00 Leveraging the Insights Gained from TIL Therapy Development to Target Wider Patient Populations**

- Increasing functionality and durability of TILs for improved therapeutic response
- Comparing clinical outcomes to characterize response rates, efficacy, durability and safety when compared to CAR-T/TCR
- Lessons learned from CAR-T: adding targeted co-stimulation to TIL therapies

**Zachary Roberts,** Chief Medical Officer, **Instil Bio, Inc**

**Madan Jagasia**, Senior Vice President Medical Affairs, **Iovance Biotherapeutics**

## Workshop C

**8.00 Setting Up Future Proof Supply Chain Operations for Cell & Gene Therapy**

- Understand key parameters that impact supply chain ops for cell and gene therapy
- Share learnings from the industry
- Discuss core capabilities and investments for setting up cell and gene therapy platform operations
- Explore key considerations for setting up the organization

**Oliver Eitelwein**, Partner, Health & Life Sciences, **Oliver Wyman**

## Workshop D

**8.00 Utilizing Multiplex Gene Engineering for Development of Off-the-Shelf Products**

- Fine-tuning the expression of multiple genes in one gene-engineering step
- Maximizing efficacy through simultaneous addition of multiple CAR molecules and activating cytokines/receptors
- Developing 'universal' allogeneic cells to enable large-scale clinical application and increase accessibility

**Sven Kili**, Chief Executive Officer, **Antion Biosciences**

**Vipin Suri**, Chief Scientific Officer, **Catamaran Bio**

**Birgit Schultes**, Senior Vice President, **Intellia Therapeutics**

## Workshop E

**8.00 Advancing Cryopreservation to Accelerate Development of Safer Allogeneic Cell Products**

- Developing robust cryopreservation protocols for the supply and transport of off-the-shelf products in the midst of global disruptions
- Optimizing cryopreservation media and storage in the clinical setting

**Zhimei Du**, Vice President of Process Development, **Atara**

**Arnaud Deladeriere**, Director of Process Development, **Triumvira Immunologics**

**Damien Hallet**, Vice President, Head of CMC, **Affini-T Therapeutics**

**10.00 Networking**

## Workshop F

**10.30 *In Vivo* Production of Functional CAR-T Cells by mRNA Targeted Lipid Nanoparticle**

- Targeted lipid nanoparticles can effectively reprogram T-cells *in vivo* to express a CAR
- CAR-T cells produced in this manner are functional and can ameliorate pathology

**Haig Aghajanian**, Vice President of Research, **Capstan Therapeutics**

**Adrian Bot**, Chief Scientific Officer & Executive Vice President, Research & Development, **Capstan Therapeutics**

## Workshop G

**10.30 Driving Clinical Development of Off-the-Shelf Therapies to Target Solid Tumor Indications**

- What lessons can we learn from the off-the-shelf natural killer and other hematopoietic cell therapies developed for patients with haematological malignancies?
- Minimizing the risk of a genotoxic safety event with increased safety
- Emerging donor testing requirements for allogeneic cell therapies

**Michael Leek**, Executive Chairman and Founder, **TC BioPharm**

**Colleen Delaney**, Founder & Chief Scientific Officer, Executive Vice President of Research & Development, **Deverra Therapeutics**

## Workshop H

**10.30 Key Challenges & Opportunities To Fast-Track Autologous CAR-T Therapy Product to Patients**

- Discussing the building blocks of the vein-to-vein process
- Sharing opportunities to shorten the manufacturing time to bring therapies to the market faster
- Exploring beyond the manufacturing process to accelerate progression throughout the value chain

**Qi Cai**, Director of Biology, **Kite Pharma**

## Workshop I

**10.30 Paving the Road to Allogeneic CAR Therapy Manufacturing, a Case Study from a Commercial Facility Design**

- Enhancing the potential for curative treatment and commercial approval for cell and ex-vivo gene and CAR-T therapies by increasing capacity to treat larger patient populations
- Walking through case studies exploring a commercial facility design IPS recently completed to enable client late-stage clinical and commercial programs
- Gaining an understanding of approach to develop a facility program and true fit-for-purpose facility that house allogeneic CAR therapy manufacturing, automated filling line and all supporting functions

**Jason Collins**, Director of Process Architecture, **IPS**

**George Todorov**, Senior Process Engineer, **IPS**

## Workshop J

**10.30 Exploring Unique Challenges in Characterization of Complexly Engineered CAR-NK Therapies**

- How well do we understand the starting material and how significant are varying donor characteristics on the final the results?
- How can we demonstrate specificity and safety of the engineering steps?
- How well can we predict clinical results from preclinical assays?

**Joseph Gold**, Vice President of Technical Operations & Manufacturing, **Catamaran**

**Stacey Cranert**, Director of Immuno-Oncology, **Poseida Therapeutics**

**12.30 Lunch**

## Workshop K

**13.30 Designing Novel CAR Constructs with Optimized Signal Strength**

- How to improve CAR-T cell therapy with more sensitive tumor identification
- Creating novel CAR-T cells with greater antigen sensitivity for enhanced anti-tumor responses
- Providing lasting remissions from cancer with next generation CAR-T cells

**Daniel Abate-Daga**, Associate Professor, **H. Lee Moffitt Cancer Center & Research Institute & University of South Florida**

**Neil Sheppard,** Director, T-Cell Engineering Lab **University of Pennsylvania, Center for Cellular Immunotherapies**

## Workshop L

**13.30 Advancing Development & Implementation of Companion Diagnostics to Better Inform Patient Selection Criteria**

- Developing and implementing companion biomarkers for use in diagnostic testing for greater patient stratification
- Engineering companion diagnostic developments for multiple medical interventions using HLA restrictions TCR therapies as an example
- Overseeing the HLA testing landscape and implementing HLA testing in oncology to set the stage for a testing paradigm in HLA-restricted TCR therapies

**Ellie Corigliano**, Head of CDx Cell & Gene Therapy, Global Clinical Development, **GSK**

## Workshop M

**13.30 Standardizing & Integrating Digital Cell Tracking Software for Greater End-to-End Visibility**

- Discussing the business case to establish an industry standard vs develop a universal software vs implement company specific software
- Establishing standard application programming interfaces or other solutions to integrate cell tracking software with GMP and hospital systems to increase COI robustness, streamline processes and eliminate manual data entry
- Brainstorming ideas to overcome supply chain challenges and maintain a patient-centric approach during clinical and commercial expansion

**William Shingler**, Senior Director, Patient and Cell Management, **Autolus**

**Chris Baldwin**, Senior Director, Cell & Gene Therapy Supply Chain, **GSK**

## Workshop N

**13.30 Building Out Phase Appropriate Analytical Methods to Enable a Smooth Path to Market**

- What does it mean to have a phase appropriate method development/ validation and why do we need it?
- How does process validation and analytical method validation overlap in later stages of development?
- What are health agency requirements/expectations vs what can be delivered?

**Nicole Hilgraf**, Director, CMC Regulatory Affairs, **Allogene Therapeutics**

**Damien Fink**, Director of Analytical Development, **Century Therapeutics**

**Elena Peletskaya**, Senior Scientific Director, GDE Portfolio Technical Strategy, **Bristol Myers Squibb**

## Workshop O

**13.30 Innovating New Economic Health Models to Bring the Value of Personalized Therapies to Market**

- Discussing whether the price of currently marketed CAR-T therapies represent true value for money
- Determining a sustainable price level for cell therapies considering the expected growth of treatable cancer types

**15.30 Networking**

### 16.00 CAR-TCR Think-Tank

This exciting addition to the program is an exclusive invite-only session, with top C-Level Executives gathering in a closed room panel to discuss the most pressing challenges facing the CAR-TCR field and sharing thought leadership on how to drive the cell therapy field into a new era of more accessible 'curative' therapies.

**Luis Borges**, Chief Scientific Officer, **Century Therapeutics**
**Helen-Tayton Martin**, Chief Business Officer, **Adaptimmune**
**Adrian Bot**, Chief Scientific Officer & Executive Vice President, Research & Development, **Capstan Therapeutics**

### 16.00 Investors Roundtable

Gathering expert venture capitalists, business angels and corporate venture funds, this is an exclusive opportunity to gain insights into the current priorities of investors and learn how to set your company apart to raise financing and secure reliable streams of capital.

### 17.00 Diversity in CAR-TCR

Therapeutic success of cell therapies goes deeper than science. The industry must overcome diversity barriers as a priority in both a workplace and clinical setting to ensure that the best-in-class cell therapies reach the patients that need them. This includes elevating a diverse and inclusive workforce and ensuring representative patient sample populations in clinical trials to widen the therapeutic impact. Join this session to learn directly from the experiences of industry professionals to understand diversity barriers to strive for a more representative, diverse and inclusive industry. Furthermore, hear about the innovative solutions posed by HR leaders, clinical trial investigators and patients themselves with key take-aways to bring into your own organization.

**Angela Justice**, Chief People Officer, **TCR² Therapeutics**
**Brad Hartman**, Chief People Officer, **Be Biopharma**

**18.30 Ambassador Receptions hosted by Precision Advance.**

PRECISION ADVANCE the cell & gene therapy collective™

TERUMO




REGISTER BY SEPTEMBER 18 TO SAVE $150

CONTENTS
WELCOME
WHAT'S NEW FOR 2022
SPEAKERS
AGENDA AT A GLANCE
DEEP DIVE DAY WORKSHOPS
DEEP DIVE DAY BOOTCAMPS
FOCUS DAY
DISCOVERY TRACK
TRANSLATION TRACK
CLINICAL MANAGEMENT TRACK
EARLY PHASE DEVELOPMENT TRACK
MANUFACTURING TRACK
CMC/ANALYTICS TRACK
LOGISTICS TRACK
MARKET ACCESS TRACK
PARTNERS
WHO WILL YOU MEET
PRICING & DISCOUNTS

REGISTER NOW

**7.00 Networking**

**8.00 Supercharging Fundamental Knowledge & Understanding of CAR-TCR Biology & Immunological Function**

This 101 Bootcamp covers the fundamentals of CAR-TCR biology and applications in interactive sessions led by industry leaders, to armor the next generation of CAR-TCR enthusiasts with the knowledge to reach that curative endpoint in oncology and beyond.

- Reviewing the growth of the CAR-T landscape from conception and first approval
- Understanding the mechanisms of actions, biological endpoints and results of pivotal clinical trials
- Glimpsing to the future: how do we get to the 'curative' endpoint?

**Stanley Frankel**, Chief Medical Officer, **Cytovia Therapeutics**

**Tony Ho**, Industry Expert, **Self Employed, Previously CRISPR Therapeutics**

**Jens Hasskarl**, Chief Medical Officer, **Tigen Pharma**

**10.00 Networking**

**10.30 Overcoming Mechanisms of Treatment Resistance of CAR-TCR Engineered T-Cells in Solid Tumors**

With poor prognosis rates in those who relapse after CAR-T therapy, more is needed to overcome mechanisms of resistance. Join this interactive deep-dive to brainstorm the approaches which are overcoming this resistance to supercharge CAR-TCR therapies against solid tumors.

- Exploring how to overcome tumor resistance and antigen loss through construct design and multiple antigen targeting
- Outlining methods to target antigen negative disease and increase response rate
- Overcoming immunosuppressive barriers to conquer the tumor microenvironment to inform future drug design and combination approaches

**Daniel Powell**, Associate Professor of Pathology & Lab Medicine, **University of Pennsylvania**

**Eric von Hofe**, Senior Advisor, **AffyImmune**

**12.30 Lunch**

**13.30 Exploring the Advantages & Applications of CAR-T Technology Beyond Oncology**

The number of potential targets for CAR-T therapy is expanding, allowing for the industry to widen their focus to include non-oncology indications. Join this interactive session to understand which technologies are paving the way beyond oncology to infuse your own pipeline development.

- Utilizing CAR technology for regenerative medicine (including degenerative diseases, fibrosis, chronic inflammation and myasthenia gravis)
- Generating a universal CAR approach for allogeneic therapies ('off-the-shelf') without the need of immunosuppression
- Working towards providing therapies for anyone, anytime, anywhere

**Miloš Miljković**, Chief Medical Officer, **Cartesian Therapeutics**

**Marko Radic**, Associate Professor of Microbiology, Immunology & Biochemistry, **University of Tennessee Health Science Center**

**Samik Basu,** Chief Scientific Officer, **Cabaletta Bio**

**15.30 Networking**

NEW

**16.00 CAR-TCR Think-Tank**

This exciting addition to the program is an exclusive invite-only session, with top C-Level Executives gathering in a closed room panel to discuss the most pressing challenges facing the CAR-TCR field and sharing thought leadership on how to drive the cell therapy field into a new era of more accessible 'curative' therapies.

**Luis Borge**s, Chief Scientific Officer, **Century Therapeutics**
**Helen-Tayton Martin**, Chief Business Officer, **Adaptimmune**
**Adrian Bot**, Chief Scientific Officer & Executive Vice President, Research & Development, **Capstan Therapeutics**

**16.00 Investors Roundtable**

Gathering expert venture capitalists, business angels and corporate venture funds, this is an exclusive opportunity to gain insights into the current priorities of investors and learn how to set your company apart to raise financing and secure reliable streams of capital.

**17.00 Diversity in CAR-TCR**

Therapeutic success of cell therapies goes deeper than science. The industry must overcome diversity barriers as a priority in both a workplace and clinical setting to ensure that the best-in-class cell therapies reach the patients that need them. This includes elevating a diverse and inclusive workforce and ensuring representative patient sample populations in clinical trials to widen the therapeutic impact. Join this session to learn directly from the experiences of industry professionals to understand diversity barriers to strive for a more representative, diverse and inclusive industry. Furthermore, hear about the innovative solutions posed by HR leaders, clinical trial investigators and patients themselves with key take-aways to bring into your own organization.

**Angela Justice**, Chief People Officer, **TCR² Therapeutics**

**Brad Hartman**, Chief People Officer, **Be Biopharma**

**6.30 Ambassador Receptions hosted by Precision Advance and Terumo BCT**

PRECISION ADVANCE the cell & gene therapy collective™ TERUMO

**7.00 Networking**

## Focus Day - Track A

### Enhancing Efficacy with Combination Therapy

**9.00 Overcoming the Challenges & Limitations of Monotherapy with Combinations**

- Mapping out the challenges of monotherapy for cell-based and non cell-based forms to identify their limitations and how combinations can help
- Assessing the success stories and failures to take key learnings into future investigations
- Using combination therapy to provide a personalized medicine to streamline clinical development and path to market

**Daniel Corey**, Chief Scientific Officer, **CERo Therapeutics, Inc**

**9.30 Enabling Cell Therapy in Solid Tumors by Reprogramming the Tumor Microenvironment with TLR9 Stimulation & Novel Delivery Technology**

- Exploiting a tailored immunomodulation approach to overcome suppressor cells of the liver tumor microenvironment
- Overcoming intra-tumor pressure which limits cell therapy and immunomodulator delivery in many solid tumors
- Surpassing the challenges of cell therapy performance in solid tumors with innovative drug-device combinatorial strategies

**Steven Katz**, Chief Medical Officer, **TriSalus Life Sciences**

**10.00 Rationalizing Effective Phase 1 Trial Design for Combination Therapies: Combining Mesothelin-Specific CAR-T (huCART-meso) Cells with Oncolytic Virus VCN-01**

- Overcoming the exclusion and suppression of T-cells by the tumor microenvironment with CAR-T therapy in solid tumors with combination therapies
- Utilizing VCN-01, a PH20 hyaluronidase-armed oncolytic virus, to degrade the tumor extracellular matrix, reprogram the tumor microenvironment and draw T-cells into tumor lesions
- Designing a combination trial NCT05057715 to establish the safety, feasibility and preliminary efficacy of a combination of huCART-meso cells and VCN-01 in patients with pancreatic or ovarian cancer

**Neil Sheppard**, Director, T-Cell Engineering Lab, **University of Pennsylvania**, **Center for Cellular Immunotherapies**

## Focus Day - Track B

### Innovations in Gene Engineering & Editing

**Chair: Gregory Fiore**, Chief Executive Officer, **Exacis Biotherapeutics**

**9.00 Understanding the Transformative Impact Gene Engineering has had on the Cell Therapy Field, Taking Translational Learnings & Uncovering Future Challenges**

- Exploring the current landscape of technologies which are supercharging cell therapies
- Harnessing translational learnings from clinical failures to avoid further difficulties
- What are the key focus areas to continue rapid growth of cell therapies with gene innovations?

**Tony Ho**, Industry Expert, **Self Employed, Previously CRISPR Therapeutics**

**Gene Tech 101**

This dedicated quick-fire session is your gene editing roadmap to understanding the pros, cons and applications of the key gene editing technologies that are spearheading the cell therapy field.

**9.30 Harnessing the Power of Epigenetic Editing for Gene & Cell Therapy**

**Blythe Sather**, Vice President, Head of Research, **Tune Therapeutics**

**9.40 Improving Manufacturability of Multiplex Edited Allogeneic CAR-T Cells Using Cytosine Base Editing**

**Melissa Le**, Scientist, **Beam Therapeutics**

**9.50 Harnessing a Safer Piggybac System, a Virus-Free Vector System for Next Generation Cell & Gene Therapy**

**Sareina Wu**, Founder & Chief Executive Officer/Chief Scientific Officer, **Genome Frontier Therapeutics**

**10.00 Making RNA Editing a Reality in Cell Therapy**

**Miloš Miljković**, Chief Medical Officer, **Cartesian Therapeutics**

**10.10 Editing with High Precision & Activity with TALEN Cellectis**

**10.20 Q&A Session**

## Focus Day - Track C

### Achieving Success in the Solid Tumor Setting

**9.00 Panel Discussion: Brainstorming the Challenges to Addressing & Overcoming the Solid Tumor Microenvironment**

**Erika von Euw**, Vice President, Discovery & Translational Research, **Devarra Therapeutics**

**Lan Cao**, Vice President, Head of Cell Therapy Innovation, Oncology Cell Therapy & Therapeutic Area Unit, **Takeda**

**Stunting Solid Tumors: Modality 101**

Twenty minute back-to-back presentations will provide a comprehensive insight into how to tackle the solid tumor interface with different immune cells and modalities.

**9.30 CAR-Macrophages (CAR-M): A Novel Approach to Solid Tumor Immunotherapy**

**Michael Klichinsky**, Chief Scientific Officer & Co-Founder, **Carisma Therapeutics**

**9.50 Dialling Up the Heat on Cold Tumors with CAR-NK Therapy**

**Yu-Waye Chu**, Chief Medical Officer, **Fate Therapeutics**

**10.10 Q&A with the Modality Experts**

- Ask our cell and modality experts your burning questions

**10.30 Networking**

## Assessing Combination Approach Case Studies to Fuel Pipeline Strategy

**11.00 Combination Immunotherapy of Adoptive T Cell**

- Therapy with Hyaluronic Acid (HA) Nanogel Based
- Cancer Vaccine

**Hiroshi Shiku**, Professor, **Mie University Graduate School of Medicine**

**11.30 Roundtable: Evaluating the Synergistic Potential of Combination with Anti-PD1 & Other Frontline Treatments to Distinguish the Best Combination Approach**

*Practical and highly interactive breakout-style roundtables where attendees can crowd-source solutions and share their opinions around cell therapy combinations with frontline treatments. This is a valuable opportunity for you to voice your experiences and debate best practice while identifying unique solutions.*

**Amy Jensen-Smith**, Senior Director, Head of Discovery Research, **SOTIO Biotech**

## Providing Supplementary Functionality to a Cell with New Gene Additions

**11.00 Harnessing CRISPR to Knock Out Checkpoint Inhibitors to Enhance CAR-NK Function**

- Detailing the technology of knocking out checkpoints and inhibitory receptors to overcome the immunosuppressive tumor microenvironment
- Presenting preclinical data for multiple myeloma
- Detailing plans to expand to the clinic

**Michael O'Dwyer**, Chief Scientific Officer, **ONK Therapeutics**

**11.30 Engineering Solid Tumor T Cell Therapies With Multi-Function Integrated Circuits Delivered by CRISPR Gene Editing**

- Implementing site-specific integration of large transgene cassettes to increase design space and predictability of cell therapy programming
- Providing ddditional constitutive and antigen-inducible synthetic functions to increase drug potency
- Harnessing logic gate targeting of tumor antigens to increase therapeutic index of higher potency drug designs

**Aaron Cooper**, Senior Director of Synthetic Biology, **ArsenalBio**

## Stunting Solid Tumors: Modality 101 Continued

**11.00 Overcoming Major Barriers of Solid Tumors with Genetic & Epigenetic Reprogramming of CAR-T cells**

**Gary Lee**, Chief Scientific Officer, **Lyell Immunopharma**

**11.20 Extending the Success of TIL Therapies in Solid Tumors – What we Have learned & Where do we go Next?**

**Parameswaran Hari**, Senior Vice President Clinical Sciences, **Iovance Biotherapeutics**

**11.40 Developing Customizable Multiplexed TCR Therapy To Treat A Wide Range of Patients with Cancers**

**Gavin MacBeath, Chief Scientific & Operations Officer, TScan Therapeutics**

**12.00 Q&A with the Modality Experts**

- Ask our cell and modality experts your burning questions

**Gary Lee**, Chief Scientific Officer, **Lyell Immunopharma**

**Gavin MacBeath**, Chief Scientific & Operations Officer, **TScan Therapeutics**

**Parameswaran Hari**, Senior Vice President Clinical Sciences, **Iovance Biotherapeutics**

**12.30 Lunch & Networking**

REGISTER BY SEPTEMBER 18 TO SAVE $150

CONTENTS
WELCOME
WHAT'S NEW FOR 2022
SPEAKERS
AGENDA AT A GLANCE
DEEP DIVE DAY WORKSHOPS
DEEP DIVE DAY BOOTCAMPS
FOCUS DAY
DISCOVERY TRACK
TRANSLATION TRACK
CLINICAL MANAGEMENT TRACK
EARLY PHASE DEVELOPMENT TRACK
MANUFACTURING TRACK
CMC/ANALYTICS TRACK
LOGISTICS TRACK
MARKET ACCESS TRACK
PARTNERS
WHO WILL YOU MEET
PRICING & DISCOUNTS

REGISTER NOW

## Learning from Previous Failures to Supercharge Safe & Efficacious Combination Investigations

**13.30 Engaging & Empowering the Innate Immune System: FLEX-NK™ Engager Antibodies & IPSC Derived NK Cells (iNKs)**

- Describing the structure and function of FLEX-NK engagers
- Harnessing iNK function for the next generation of cell therapies
- Leveraging the potential synergy of combination therapy

**Stanley Frankel**, Chief Medical Officer, **Cytovia Therapeutics**

**14.00 Creating Effective Preclinical Models for Combination Studies in Cell Therapy**

- Elucidating the case for combining cell therapy with checkpoint molecules and other interventions
- Building models to recapitulate key immunologic mechanisms underlying anti-cancer responses
- Providing a case study of invariant natural killer cell therapy combos

**Marc van Dijk**, Chief Scientific Officer, **MiNK Therapeutics**

## Exploiting iPSC-Derived Therapies for the Next Wave of Cell Therapy

**13.30 Genetically Modifying iPSCs for Development of Universal Cell Therapy**

- Discussing the impact of timing duration and intensity of notch signaling on T-cell lineage commitment
- Harnessing scaled iPSC-T differentiation
- Optimizing process development in the era of big data

**Christopher Bond**, Vice President Preclinical & Translational Sciences, **Notch Therapeutics**

**14.00 Leveraging mRNA Based Gene Editing to Optimize Advancement of Safe & Cost-Effective iPSC Products**

- Engineering stealthing edits and performance enhancements to iPSCs with mRNA-based gene edited tools for enhanced persistence and potency
- Avoiding viral and DNA vectoring approaches and using a fusogenic lipid delivery system to add CARs safely
- Expanding iPSCs to yield large numbers of allogeneic NK and T-cell therapies within short time frames for fast delivery to patients

**Gregory Fiore**, Chief Executive Officer, **Exacis Biotherapeutics**

## Implementing Adoptive Cell Therapy Strategy into Preclinical & Clinical Investigations

**13.30 Developing & Validating a Multiplexing Approach for Co-Targeting Tumors**

- Summarizing a novel CAR Platform, a parallel (p)CAR, consisting of a CD-28-containing CAR and a 4-1BB containing chimeric co-stimulatory receptor
- Demonstrating superior restimulation potential *in vitro* and superior efficacy in model systems
- Exhibiting superior *in vivo* activity in a range of cell line and patient derived xenograft models when compared to linear CAR designs

**Marc Davies**, Vice President, CAR Engineering, **Leucid Bio**

**14.00 Utilizing Tumoral Biomarkers to Optimize Patient Selection**

**14.30 End of Focus Day**

> "Converging with other thought leaders to discuss the successes and challenges of T-cell therapeutics is important for progress in the field. The CAR-TCR Summit proves to a premier opportunity to share and learn from each other."
>
> **Amy Jensen-Smith**, Senior Director, Head of Discovery Research, **SOTIO Biotech**

# Plenary Sessions



DISCOVERY TRACK | TRANSLATION TRACK | CLINICAL MANAGEMENT TRACK | EARLY PHASE DEVELOPMENT TRACK | MANUFACTURING TRACK | CMC/ANALYTICS TRACK | LOGISTICS TRACK | MARKET ACCESS TRACK

## DAY 1 PLENARY SESSIONS SEPTEMBER 20

**7.30 Registration**

**8.30 Chair's Opening Remarks**

**8.45 Industry Leaders' Fireside Chat**

**Christina Coughlin**
Chief Executive Officer
**Cytoimmune Therapeutics**

**Bryan Campbell**
Vice President, Cell Therapy Franchise
**Bristol Myers Squibb**

**Pascal Touchon**
Chief Executive Officer
**Atara Bio**

**Warner Biddle**
SVP & Global Head of Commercial
**Kite Pharma**

**9.15 Your Future CAR-TCR Success Stories, Delivered by Lonza**

**Tamara Laskowski**
Head of Clinical Development Personalized Medicine
**Lonza**

**Joseph Garrity**
Head of Commercial Development Cell & Gene Therapies
**Lonza**

**9.45 Leveraging Combinations to Enhance CAR-NK Activity in Solid Tumors by Flipping the Tumor Microenvironment**

**Christina Coughlin**
Chief Executive Officer
**Cytoimmune Therapeutics**

**10.15 Networking & Refreshments**

## DAY 2 PLENARY SESSIONS SEPTEMBER 21

**7.00 Emily Whitehead Foundation 5k Run/Walk**

#StepTowardsACure - Join the Emily Whitehead Foundation and CAR-TCR for a run (or walk) together around Boston! Participate in person or virtually, with funds raised benefiting the Emily Whitehead Foundation.
***Sign up now!***

emily whitehead foundation
activate the cure for childhood cancer

**8.00 Breakfast Briefing**

BIO-RAD | PROJECTFARMA

**8.30 Chair's Opening Remarks**

**8.40 Incorporating Patient Insights & Engagement for Clinical & Commercial Success**

**Maria Kirsch**
General Manager, Patient Services
**EVERSANA**

**Seth Gordon**
General Manager
**EVERSANA™ ENGAGE**

**9.10 Switchable CAR-T Cells (CLBR001 + SWI019) in Patients with B Cell Malignancies**

- The switchable CAR-T cell platform was designed as a method of tuning the level of activity of CAR-T cells after adoptive transfer to the patient
- The platform can be universally applied to any tumor antigen and has been demonstrated as efficacious in more than a dozen preclinical models
- Here we present early results of the first in human clinical trial using the universal CAR-T cell product (CLBR001) and a CD19-targeted switch (SWI019)

**Travis Young**
Vice President Biologics
**Calibr at Scripps Research**

**9.20 Flex with Confidence: Elevate your Manufacturing Strategy with a Scalable Cell Expansion Platform**

- How to automate early in process development and transition into commercial production with a single system
- Benefits of the hollow fiber perfusion bioreactor in maintaining cell health while increasing efficiency and simplifying the manufacturing process
- How software features enable scale and GMP compliance

**Wenyan Leong**
Senior Marketing Manager, Cell Therapy Solutions
**Terumo Blood and Cell Technology**

**10.00 Review of Current Autologous & Allogeneic Cell Therapy Processing & Data Transfer Strategies, Gaps & Key Requirements To Next Generation Platforms**

- Review of current autologous and allogeneic cell therapy processing and data transfer strategies, gaps, and key requirements to next generation platforms
- Next generation autologous and allogeneic cell therapy processing and automation strategies with Thermo Fisher Scientific platforms
- Considerations for future automation strategies and strategic design and development new platforms

**Xavier de Mollerat du Jeu**
Senior Director of Research & Development
**Thermo Fisher Scientific**

**Ivie Aifuwa**
Associate Director, Process Technology Development
**Bristol Myers Squibb**

**10.30 Tech Slam & Networking**



REGISTER NOW

# Plenary Sessions



## DAY 3 PLENARY SESSIONS — SEPTEMBER 22

**8.00** **Breakfast Briefing** — TrakCel

**8.30** **Chair's Opening Remarks**

**8.40** **Next Generation Leader's Fireside Chat**

**Adrian Bot**
Chief Scientific Officer & Executive Vice President, Research & Development
**Capstan Therapeutics**

**Nicholas Boyle**
Co-Founder & Chief Executive Officer
**Abintus Bio**

**Arthur Stril**
Chief Business Officer
**Cellectis**

**Gary Lee**
Chief Scientific Officer
**Lyell Pharma**

**9.00** **Building Next-Gen Commercial Cell Therapy Faciliites**

- Hear from industry experts on their approach to building an innovative cell therapy manufacturing facility
- Gain key insights into building out infrastructure, proper project workstreams and quality systems
- Learn about phased implementation, CQV strategies, and regulatory challenges

**Anshul Mangal**
President
**Project Farma & Precision ADVANCE**

**9.30** **Characterized Starting Materials for Accelerated & Scalable CAR-TCR Therapies**

- Leverage access to highly annotated diseased biomaterials to enhance target discovery
- Outline how highly characterized donor source materials impact consistency from process development to manufacturing
- Strengthen downstream processing by incorporating multi-omic analytics, including flow cytometry and single cell sequencing of the cell-based starting materials

**Dominic Clarke**
Chief Technical Officer, Cell & Gene Therapy
**AllCells, A Discovery Life Sciences Company**

**Aaron Vernon**
Vice President, Technical Operations
**TCR2 Therapeutics**

**John Khoury**
EVP
**Project Farma**

**Sumit Verma**
SVP
**Commercial Operations, Iovance**

**10.00** **Networking & Tech Slam**

**11.00** **Tracked Sessions Begin**

**15.00** **Afternoon Break**

**16.00** **Generation of Alpha-Beta T-Cells From iPSCs for the Development of Off-The-Shelf CAR-T Cells for Treatment of Hematological Malignancies & Solid Tumors**

- The use of clonally-derived, master induced pluripotent stem cell (iPSC) lines is an attractive source for the renewable manufacture of precisely-engineered, homogenous CAR-T cell products that can be fully characterized, stored and administered on-demand for broad patient access
- Update on the development of our CAR-T cell pipeline, including FT819, the first-ever T-cell therapy manufactured from a clonal iPSC line to undergo clinical investigation
- The clonal master iPSC line for FT819 is created from a single iPSC that has a novel CD19-targeted 1XX CAR construct integrated into the T-cell receptor alpha constant locus, ensuring complete bi-allelic disruption of T-cell receptor expression and promoting uniform CAR expression

**Bob Valamehr**
Chief Research & Development Officer
**Fate Therapeutics**

**16.30** **A Fully Allogeneic T SCM-Based TCR-T Platform for Oncology & Beyond**

- Poseida has adapted their nonviral piggyBac, Cas-CLOVER gene-editing and booster molecule technologies for production of highly functional allogeneic TCR-T
- Proof-of-concept TCR-T cells against NY-ESO-1 and COVID are comprised of a high percentage of memory cells, and demonstrate robust *in vivo* cellular kinetics and potency
- Multi-targeting CAR / TCR cells leverage the advantages of both approaches

**Devon Shedlock**
Chief Scientific Officer
**Poseida Therapeutics**

**17.00** **Chair's Closing Remarks**

**17.15** **End of Day 3**

VIEW DAY 1 PLENARY SESSIONS





# DISCOVERY TRACK

- TRANSLATION
- CLINICAL MANAGEMENT
- EARLY PHASE DEVELOPMENT
- MANUFACTURING
- CMC/ANALYTICS
- LOGISTICS
- MARKET ACCESS

Featuring cutting-edge research in CAR and TCR development with next generation *in vivo* gene engineered approaches, novel construct design and advanced discovery of new epitope targets for solid tumors, hear from never-before seen companies and glimpse breaking preclinical data. Discover disruptive technologies from the leaders shaking up the future landscape of CAR and TCR development.

## CONFERENCE DAY 1 | SEPTEMBER 20, 2022

- Improving T-Cell Functionality & Efficacy of TCRs with Powerful Novel Platforms
- Next Generation Transduction & Delivery

## CONFERENCE DAY 2 | SEPTEMBER 21, 2022

- Accelerating Target Identification & Validation
- The Next Frontier: Enhancing Functional CAR-T Activity

## CONFERENCE DAY 3 | SEPTEMBER 22, 2022

- Overcoming Autoimmunity with Engineered Cells
- Supercharging Development of Novel CAR Architecture & Design

## DISCOVERY TRACK

### MORNING SESSIONS

**Improving T-Cell Functionality & Efficacy of TCRs with Powerful Novel Platforms**

**11.15 A Functional Approach to Identifying & Engineering TCRs Results in Highly-Potent & Specific TCRS for TCR-T Cell Therapy**

- Novel strategies and functional platforms for identifying safe and specific TCRs
- Use of high diversity libraries to screen for off-targets

**Leah Sibener**, Co-Founder, Vice President of Therapeutic Discovery, **3T Biosciences**

**11.45 The *In Vitro* Measure of Avidity Between CAR-T/TCR-T & Tumor Cells Predicts Optimal *In Vivo* Response**

- We present data discussing how increased specific avidity, those TCR's with strongest antigen binding with the lowest background, correlate with improved TCR function *in vitro* and *in vivo*
- How CAR-T and TCR-T avidity is significantly more correlative to *in vivo* outcome than either cytotoxicity assays or IFN-g release
- Methods for using cell avidity to screen constructs and more reliably select lead candidates

**Will Singleterry**, Commercial Director - Immuno-Oncology, **LUMICKS**

**12.15 Design of Novel Synthetic Hybrid Receptors that Fully Engage Proximal TCR Signaling**

- Design of TCR/CAR hybrid receptors engaging the entire TCR complex
- Recapitulates a more physiological TCR signaling into T-cells
- Enhanced sensitivity and anti-tumor immunity

**Sylvain Simon**, Postdoctoral Fellow, **Fred Hutchinson Cancer Research Center**

**12.45 Hosted Lunch**

### POST-LUNCH SESSIONS

**Next Generation Transduction & Delivery**

**13.45 Next Generation CAR-T: Who Needs Manufacturing?**

- Overview of technology to generate CAR-Ts *in vivo*

**Knut Niss**, Chief Technology Officer, **Mustang Bio**

**14.15 Automated Synthetic Biology Solutions for Optimizing CAR-T Development Workflows**

- BioXp DNA-based solutions have enabled researchers to optimize CAR generation workflows, and the assembly of optimized CARs.
- BioXp mRNA solutions can accelerate the generation of mRNA for T cell manipulation in cell therapy, enabling rapid candidate screening through transient modulation of cellular phenotypes.
- Multiple BioXp solutions can be leveraged to build datasets informing hypothesis generation in a scalable manner

**Ankita Das**, Senior Product Manager, RNA/DNA, **Codex DNA**

**14.45 Panel Discussion: Exploring the Future of *In Vivo* Delivery to Usher in New Era of Cell Therapy**

- Discussing the value of *in vivo* engineering to the patient
- What mechanisms are there to supports cell expansion *in vivo?*
- How can we improve safety, dosing and efficacy by using mRNA to create CAR-T cells *in vivo*?

**Jacob Becraft**, Co-Founder, Chief Executive Officer, **Strand Therapeutics**

**Bakul Gupta,** Chief Executive Officer, **Immtune Therapies**

**David Fontana,** Chief Business & Strategy Officer, **Umoja Biopharma**

**Knut Niss**, Chief Technology Officer, **Mustang Bio**

**15.15 Tech Slam**

### AFTERNOON SESSIONS

**Next Generation Transduction & Delivery**

**16.15 Targeting Solid Tumors with a Universal CAR & Small Molecule Bispecific Adapters (Tumor Tags)**

- Novel targeting of tumor cells and stromal elements will be discussed
- The utility of a universal "TagCAR" in *ex vivo* or *in vivo* approaches with a cocktail of tumor tags will be the focus

**David Fontana**, Chief Business & Strategy Officer, **Umoja BioPharma**

**16.45 TcBuster Transposon System for Engineering CAR/TCR Immune Cell Therapies**

- Non-viral gene editing system for the introduction of multi-cistronic vectors for CAR and TCR Therapies
- Improved cargo capacity, reagent manufacturing timelines, and safety profile compared to viral gene editing approaches

**David Hermanson**, Senior Manager of R&D Applications, Cell and Gene Therapy, **Bio-Techne**

**17.15 *In Vivo* Generation of Functionally Active CAR-T Cells**

- Non-viral approaches for *in vivo* T-cell transfection
- Comparison between *ex vivo and in vivo* CAR-Ts
- Long term persistence with *in vivo* generated CAR-Ts

**Bakul Gupta**, Chief Executive Officer, **ImmTune Therapies**

**18.00 Drinks Reception**

## DISCOVERY TRACK

### MORNING SESSIONS

**Accelerating Target Identification & Validation**

**10.30 Tech Slam**

**11.30 Discovery of TCRs Targeting Novel Antigens Using Deep Immunomics**

- Discovery and development of novel TCR-based therapeutics using the Deep Immunomics platform
- Identification of therapeutically relevant TCRs against both well-characterized and novel targets across multiple HLA types
- Applying computational approaches to advance TCR Discovery for novel targets

**Dan MacLeod**, Vice President, Discovery, **ImmunoScape**

**12.00 Writing the Future of Cell Therapies Using the Twist Biopharma Library of Libraries**

- Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody and TCR discovery libraries
- A highly diverse synthetic naïve scFv and VHH antibody phage display libraries to discover targeting domains for CAR-T constructs
- A combinatorically assembled TCR libraries from gene fragments
- POC data on how these technologies can be utilized for cell therapies

**Aaron Sato**, Chief Scientific Officer, **Twist Bioscience**

**12.30 Functional Decoding of Tumor Immune Repertoire Through Massively Parallel TCR Gene Synthesis & Screening**

- We developed a technology to synthesize thousands of paired, full-length, expressible TCR genes affordably from single-cell sequencing data
- Using this technology, we synthetically recreated the immune repertoire in the tumor microenvironment and functionally screened this immune repertoire to identify rare, potent tumor-reactive TCRs
- The process can be affordably repeated for every patient, enabling a fully personalized TCR therapy

**Ely Porter**, Co-founder & Chief Technology Officer, **Rootpath**

**13.00 lunch**

### POST-LUNCH SESSIONS

**Accelerating Target Identification & Validation**

**14.00 High-Precision Cell-Based Characterization & Optimization Platform to Select & De-Risk Clinically Deployable TCRs**

- Cell-based methodologies to accurately rank TCR candidates
- Determining a TCRs cross-reactivity and alloreactivity profile
- Overcoming natural TCR limitations by enhanced optimization workflow

**Luke Pase**, Chief Technology Officer, **Anocca**

**14.30 Adaptive's TCR Discovery Platform & Immune Monitoring of CAR/TCR products**

- Overview of Adaptive's TruTCR and TruAb discovery process for identifying, characterizing and ranking of fully human, naturally occurring receptors as therapeutic candidates.
- Use of T cell receptor sequencing to characterize cell therapy products.
- Monitoring of T cell responses and T cell products with long-term follow-up applications.

**Erik Yusko**, Senior Director, Drug Discovery, **Adaptive Biotechnologies**

**15.00 Panel Discussion: Driving Target Discovery with Novel AI Technology**

- Discussing how to advance the discovery of new epitope targets for solid tumors using innovative high throughput screening and computational AI techniques
- How can we better leverage bioinformatic platforms to advance drug discovery?

**Dan MacLeod**, Vice President, Discovery, **ImmunoScape**

**Ely Porter**, Co-founder & Chief Technology Officer, **Rootpath**

**Luke Pase**, Chief Technology Officer, **Anocca**

**15.30 Networking**

### AFTERNOON SESSIONS

**The Next Frontier: Enhancing Functional CAR-T Activity**

**16.30 BEAT Technology to Enhance CAR-T Cell Therapy in the Solid Tumor Setting**

- Overcoming problems of persistence, the immunosuppressive tumor microenvironment and antigen loss through the addition of a BEAT or bi-specific engager of antigen presenting cells and T-cells, to CAR-T cell therapy
- Preclinical evidence demonstrates the therapeutic potential of the use of the BEAT in addition to CAR-T cell therapy for the treatment of solid tumors

**Sam Cobbs**, Chief Executive Officer, **Currus Bio**

**17.00 TALXcell Genome Editing Platform: A Novel TAL-Based Nuclease Technology**

- TALXcell is a novel TAL-based nuclease, consisted of a T-less TALE DNA binding domain and a novel nuclease domain
- Eliciting high editing efficiency, comparable to the CRISPR-Cas9 (KO and KI)
- Enabling editing anywhere in the genome with no sequence restrictions to generate functional CAR-T cells

**Youngzee Song**, R&D Manager, **Thermo Fisher Scientific**

**17.30 Advances in the BOXR Platform for Solid Tumor Cell Therapies**

- Preclinical updates on the BOXR platform, either:
- Data from new BOXR transgenes and targets OR
- Data on BOXR T-cells in combination with other therapeutics (e.g. cytokines)

**Geoff Hodge**, Chief Executive Officer, **SOTIO Biotech US**

**18.00 End of Day 2**

## DISCOVERY TRACK

### MORNING SESSIONS

**Overcoming Autoimmunity with Engineered Cells**

**11.00 Optimizing the Development of CD19 CAR-T Therapy for Autoimmune Diseases**

- There is strong rationale for CD19 CAR-T therapy for use in B cell-driven autoimmune diseases but the observed toxicities associated with CAR-T administration and activation in B cell malignancies have limited investigations in autoimmune diseases
- Optimization of CD19 CAR construct characteristics and clinical trial strategies may enable safe and efficient development of this promising approach for the treatment of autoimmune diseases

**James Chung**, Chief Medical Officer, **Kyverna Therapeutics**

**11.30 Pin-Point™ – Modular Base Editing for Clinical Applications**

- Utilizing a base-editing system with aptameric guide-RNA for deaminase recruitment
- Demonstrating simultaneous targeting of several therapeutically relevant stimuli of CAR-T while retaining proliferative and cytotoxic ability
- Enabling simultaneous knock-in and knock-out to allow targeting of polygenic disorders

**Branden Smeester**, R&D Scientist, **Horizon Discovery**

**12.00 Panel Discussion - Examining the Potential of Engineered CAR T-Reg Cells for the Modulation of Antigen-Specific Responses**

- Exploring the optimal and appropriate safety profile of a CAR T-reg
- Optimizing persistence with engineered CAR T-regs to get efficient effect in autoimmunity
- How can these genetically engineered cells be used to enhance immune tolerance in autoimmune diseases?

**12.30 Lunch & Poster Session**

### POST-LUNCH SESSIONS

**Supercharging Development of Novel CAR Architecture & Design**

**13.30 CAR-T Cell-Based Targeting of Intracellular Patient-Specific Mutations**

- A novel method for the generation and screening of peptide/MHC specific scFvs
- Development of neoantigen-specific CAR-T cells that distinguish intracellular neoantigens from self-proteins
- Enhancing neoantigen recognition and killing through CAR-T cell armoring

**Daniel Powell Jr**, Associate Professor of Pathology & Lab Medicine, **University of Pennsylvania**

**14.30 Simultaneous & Sequential Multi-Antigen Targeting with a Novel Universal Immune Receptor**

- Overcoming limitations of multi-antigen targeting with UIRs
- Controllable lytic activity post-infusion to address off-tumor safety concerns

**Daniel Shelly**, Vice President Business Development & Alliances, **Prescient Therapeutics**

**15.00 Afternoon Break**

**16.00 Closing Plenary Sessions**

> "It's an outstanding opportunity to stay abreast of the latest innovations in this rapidly emerging field that is transforming the practice of medicine"
>
> **James Chung,** Chief Medical Officer, **Kyverna Therapeutics**

> "Communicating new ideas, methods, approaches, technologies with academic and industry leaders is essential, as well as strong networking potential"
>
> **Daniel Powell Jr,** Associate Professor of Pathology & Lab Medicine, **University of Pennsylvania**

VIEW DAY 1 PLENARY SESSIONS





# TRANSLATION TRACK

- DISCOVERY
- CLINICAL MANAGEMENT
- EARLY PHASE DEVELOPMENT
- MANUFACTURING
- CMC/ANALYTICS
- LOGISTICS
- MARKET ACCESS

Hear from industry experts as they showcase how to enhance translational confidence with a strategic clinical biomarker plan and supercharge data interpretation from novel preclinical models to further drive clinical development. Hear from industry experts as they showcase how to break into the hostile tumor microenvironment and leverage the power of combined modalities to meet areas of high unmet need.

## CONFERENCE DAY 1 | SEPTEMBER 20, 2022

- Identifying & Validating Biomarkers of Performance & Response
- Driving Gamma Delta Based CAR/TCR-T Target Drug Development

## CONFERENCE DAY 2 | SEPTEMBER 21, 2022

- Utilizing Innovative Preclinical Models to Drive Success
- Infiltrating Solid Tumors with a Synergistic Strategy
- Modifying the Tumor Microenvironment to Achieve Access to the Solid Tumor & Enhance Durability

## CONFERENCE DAY 3 | SEPTEMBER 22, 2022

- Improving Safety with Novel Class of Tumor Antigen Targets & Enhanced Natural Killer Cells
- Looking to the Horizons of the CAR-NK Landscape for Greater Success

## TRANSLATION TRACK

### MORNING SESSIONS

**Identifying & Validating Biomarkers of Performance & Response**

**10.30 Tech Slam**

**11.15 Identifying & Validating Biomarkers of Performance & Response**

- Strategies to identify and validate biomarkers of clinical response
- Using biomarker evidence to drive success in the clinic

**Kathryn Newhall**, Vice President, Head of Translational Research, **Cellectis**

**11.45 From Discovery to Clinic: Accelerating the Path From Discovery to a Developed Cell & Gene Therapy Product**

- Highlight the challenges with translating biomarkers and cell targets into nuclease based cell & gene therapies
- Optimizing gene editing workflows for cell & gene therapies with a simplified RUO to GMP supply chain
- Anticipating gene editing challenges through safety profiling and analytics

**Rebecca Nugent**, Vice President, Platform Research, **Synthego**

**12.15 Roundtable Discussion: Developing PK-PD Biomarkers to Measure Clinical Performance of Allogeneic Cell Products**

- Developing a biomarker assay to track progress of therapy against tumor/relapse
- Investigating biomarker of activity against agent to determine/predict negative impact of therapy
- Implementing use of predictive pharmacodynamic markers to identify patient responders to treatment

**Indu Ramachandran**, Head of Translational Development, **Century Therapeutics**

**12.45 Hosted Lunch**

### POST-LUNCH SESSIONS

**Identifying & Validating Biomarkers of Performance & Response**

**13.45 Strategies to Identify Biomarkers of Response to Genetically Engineered Cell Therapy Products**

- Blueprint of biomarker strategy that can be applied to any TCR and CAR products
- Importance of clinical sample management to obtain high impact biomarkers data
- Current status and future perspective: correlations between clinical biomarkers and efficacy of TCR and CAR products

**Lavakumar (Kumar) Karyampudi**, Director of Cell Therapies Facility, **Moffitt Cancer Center**

**14.15 Adaptation of CAR T Cells To the Central Nervous System**

- Mass cytometry reveals spatiotemporal plasticity of CAR T cells in patients
- Adaptation of CAR T cells to the central nervous niche includes distinct trafficking and metabolic signature
- CAR T cells in the central nervous system have memory-like features

**Lior Goldberg**, Pediatric Oncologist, Physician-Scientist, **City of Hope Comprehensive Cancer Center**

**Driving Gamma Delta Based CAR/TCR-T Target Drug Development**

**14.45 Panel Discussion: Leveraging Gamma Delta T-Cells for Enhanced Anti-Tumor Activity**

- Exploring the advantages of using gamma delta T-cells to accelerate cancer immunotherapy development
- Determining functional activity of different gamma delta subsets and their benefits

**Francesco Galimi**, Chief Medical Officer, **Adicet Bio**

**Mark Throsby**, Chief Scientific Officer, **Gadeta**

**Sean Mackay**, Chief Executive Officer & Founder, **IsoPlexis**

**15.15 Networking**

### AFTERNOON SESSIONS

**Driving Gamma Delta Based CAR/TCR-T Target Drug Development**

**16.15 Gamma Delta CAR-T Cells in B-Cell Malignancies**

- Summary of biological rationale supporting the use of gamma delta cells in oncology
- Phase I experience with anti-CD20 gamma delta CAR-T in non-Hodgkin lymphoma

**Francesco Galimi**, Chief Medical Officer, **Adicet Bio**

**17.15 Exploiting Gamma Delta TCR Targeting to Enable Safe & Effective Cell Therapies for Solid Tumors**

- γδ TCR are naturally selected, recognize surface targets like antibodies on transformed "stressed" tumor tissue but not healthy tissue, and are not HLA dependent
- Gadeta's TEG platform (T-cells engineered with a defined γδ TCR magnifies the potential therapeutic activity of γδ T-cells)
- The talk will highlight Gadeta's clinical and development programs

**Mark Throsby**, Chief Scientific Officer, **Gadeta**

**18.00 Drinks Reception**



REGISTER BY SEPTEMBER 18 TO SAVE $150

CONTENTS
WELCOME
WHAT'S NEW FOR 2022
SPEAKERS
AGENDA AT A GLANCE
DEEP DIVE DAY WORKSHOPS
DEEP DIVE DAY BOOTCAMPS
FOCUS DAY
DISCOVERY TRACK
TRANSLATION TRACK
CLINICAL MANAGEMENT TRACK
EARLY PHASE DEVELOPMENT TRACK
MANUFACTURING TRACK
CMC/ANALYTICS TRACK
LOGISTICS TRACK
MARKET ACCESS TRACK
PARTNERS
WHO WILL YOU MEET
PRICING & DISCOUNTS

REGISTER NOW

# TRANSLATION TRACK

## MORNING SESSIONS

**10.30 Tech Slam**

**Utilizing Innovative Preclinical Models to Drive Success**

**11.30 *In Vivo* Evaluation and Preclinical Modeling of CAR/TCR therapy**

- The use of preclinical *in vivo* modeling, safety and efficacy testing of CAR/TCR therapy
- Comparing different approaches utilizing the humanized mouse and non-human primate models

**Scott Kitchen**, Professor & Director, **University of California, Los Angeles**

**12.00 Evaluation of Safety and Efficacy of CART Therapy in PBMC Humanized Mice**

- JAX has developed a fast, sensitive and reproducible in vivo platform for evaluating CAR T therapies in PBMC humanized mice.
- The platform is being applied to both autologous and allogeneic CARTs with evaluation of cytokine release syndrome, efficacy and CART expansion with the goal to help de-risk CART pre-clinical development.

**James Keck**, Senior Director of Innovation & Product Development, **The Jackson Laboratory**

**12.30 Development of Next Generation Autologous T-Cell Therapies for the Treatment of Cancer**

- Overview of approved cell therapy products and key learnings
- Next generation approaches to meet unmet medical need in CAR refractory patients
- Biomarker guided approaches to inform on clinical outcomes and nature of treatment related toxicity

**John Rossi**, Vice President, Head of Translational Medicine, **Syncopation Life Sciences**

**13.00 Lunch & Networking**

## POST-LUNCH SESSIONS

**Infiltrating Solid Tumors with a Synergistic Strategy**

**14.00 Developing Versatile T-cell Therapies Against Extracellular, Intracellular & Planted Targets for the Treatment of Solid Tumors**

- How ARTEMIS® T-cells break through solid tumors with better infiltration and less exhaustion
- A TCR mimetic approach to target intracellular tumor antigens
- A novel "mark and kill" approach that leverages oncolytic virus to express CD19 protein on solid tumor cells and then mobilizes T-cells to eliminate the marked cancer cells

**Cheng Liu**, Founder & Chief Executive Officer, **Eureka Therapeutics**

**14.30 Bispecific-Antibody-Armed, Metabolically Enhanced Headless CAR-T Cells: Safe & Effective Serial Killers Of Solid Tumors**

- BsAb-armed hCAR-T cells are superior to non-genetically modified T-cells armed with bsAbs and mediate superior levels of cytotoxicity directed at all tested solid tumor lines
- The hCAR-T cells killed multiple tumor lines significantly better than control T-cells and secreted Th1 cytokines/chemokines at effector to target ratio (E:T) of 2:1 or 1:1
- HER2 hCAR-T cells serially killed tumor targets up to 14 days and continued to kill under *in vitro* hypoxic conditions
- Sequential targeting of positive tumors showed significantly increased cytotoxicity compared to single antigen targeting
- In this study, the researchers used Agilent Seahorse XF, Agilent xCELLigence RTCA, and Agilent NovoCyte Flow Cytometer

**Archana Thakur**, Associate Professor of Medicine, Director of Human Cellular Therapeutics cGMP Core, **University of Virginia, School of Medicine**

**15.00 Panel Discussion: New Frontiers in Cell Therapy – Optimizing Combined Approaches for Greater Persistence**

- Discussing the synergistic/additive potential of combined modalities to overcome resistance to immunotherapy
- Developing preclinical strategy to determine which combinations have the most synergistic/additive potential

**Paul Rennert**, Acting Chief Executive Officer, President, Chief Scientific Officer, **Aleta Biotherapeutics**
**Cheng Liu**, Founder & Chief Executive Officer, **Eureka Therapeutics**

**15.30 Networking**

## AFTERNOON SESSIONS

**Modifying the Tumor Microenvironment to Achieve Access to the Solid Tumor & Enhance Durability**

**16.30 Enabling Cellular Therapies for Solid Tumors by T-SIGn Vector-Mediated Reprogramming of the Tumor Microenvironment**

- Clinically validated T-SIGn vectors are dosed systemically to deliver combinations of therapeutic payloads specifically to tumors for local production within the tumor microenvironment
- Preclinical human tumor xenograft models have demonstrated marked remodelling of the tumor microenvironment following IV dosing of T-SIGn vectors with different combination payloads, leading to clearance of tumors in combination with inactive or suboptimal doses of CAR-T cells
- Natural and synthetic transgene payload combinations can be specifically designed to synergize effectively with specific CAR and other cell therapies, enabling the application of these approaches to the treatment of solid tumors

**Brian Champion,** Chief Scientific Officer, **PsiOxus Therapeutics**

**17.00 Visualize & Characterize CAR-T Biodistribution & Function in Tumors**

- Spatial localization and quantitation of CAR-T cells using RNAscope™ technology.
- Visualize CAR-T engagement and activation.
- Characterize and quantify cytokines and chemokines in the tumor microenvironment.
- Assess safety and efficacy by identifying on-target/off-tumor effects.

**Alpana Kumari,** Business Development Manager Advanced Cell Diagnostics, **a Bio-Techne Brand**

**17.30 CAR Engineered Approaches to Optimally Target the TME & Enhance Durability**

**Jim Johnston**, Chief Scientific Officer, **ImmPACT Bio**

**18.00 End of Day 2**

REGISTER BY SEPTEMBER 18 TO SAVE $150

CONTENTS
WELCOME
WHAT'S NEW FOR 2022
SPEAKERS
AGENDA AT A GLANCE
DEEP DIVE DAY WORKSHOPS
DEEP DIVE DAY BOOTCAMPS
FOCUS DAY
DISCOVERY TRACK
TRANSLATION TRACK
CLINICAL MANAGEMENT TRACK
EARLY PHASE DEVELOPMENT TRACK
MANUFACTURING TRACK
CMC/ANALYTICS TRACK
LOGISTICS TRACK
MARKET ACCESS TRACK
PARTNERS
WHO WILL YOU MEET
PRICING & DISCOUNTS

REGISTER NOW

## TRANSLATION TRACK

### MORNING SESSIONS

**Improving Safety with Novel Class of Tumor Antigen Targets & Enhanced Natural Killer Cells**

**11.00 Safely Targeting Antigens Expressed on Healthy Tissue in Solid Tumors**

- Development of two Chlorotoxin CAR-T programs which showcase a new class of tumor antigen targets
- Discussing development of an allogeneic natural killer cell therapy and the potential for combination therapy by using alongside CARs

**Jennifer Chow**, Chief Executive Officer & Managing Director, **Chimeric Therapeutics**

**Looking to the Horizons of the CAR-NK Landscape for Greater Success**

**12.00 Panel Discussion: Optimizing CAR-NK Cell Cytoxicity with Novel Engineering Strategies**

- Addressing how to enhance persistence and activation of adoptively transferred NK cell CARs
- Improving the generation of CAR-NK through retroviral transduction
- Discussing novel approaches to enhance dual targeting of tumors by natural killer cells with bispecific CARs

**Elie Haddad,** Professor, Department of Pediatrics**, University of Montreal**

**Rizwan Romee,** Associate Professor of Medicine, **Dana Farber Cancer Institute, Harvard Medical School**

**12.30 Lunch & Poster Session**

### POST-LUNCH SESSIONS

**13.30 CAR Therapy Beyond T-Cells: CAR-NK Cells or Even CAR in Stem Cells for Cancer Immunotherapy?**

- CAR-T cells have a limited efficacy in solid tumors
- CAR-NK cells may become the best strategy for off-the-shelf solid tumor CAR-therapy
- CAR in Hematopoietic stem cells (CAR-HSC) may also be an alternative strategy that would combine both CAR-T and CAR-NK cells

**Elie Haddad**, Professor, Department of Pediatrics, **University of Montreal**

**14.00 CAR-T & CAR-NK Cells Using RNA-LNP for Clinical Use**

- Design of novel bispecific CAR-T cells and improved affinity of Scfv
- Developing of platform for mRNA synthesis, purification, and encapsulation to LNP for cell therapy
- Preparation of CAR-T/CAR-NK cells using mRNA-LNP for clinical use

**Vita Golubovskaya**, Senior Director, Research & Development, Business Development, **ProMab Biotechnologies**

**14.30 Engineering Natural Killer Cells for Enhanced Targeting in Solid Tumors**

- Highlight some of the major challenges in advancing natural killer cell-based immunotherapies in solid tumors
- Describe preliminary results from a study combining allogeneic memory-like natural killer cells with long-acting IL-15 in head and neck cancer
- Highlight efforts to target membrane proximal domain of mesothelin with memory-like natural killer cell CAR

**Rizwan Romee**, Associate Professor of Medicine, **Dana Farber Cancer Institute, Harvard Medical School**

**15.00 Afternoon Break**

**16.00 Closing Plenary Sessions**

> "This meeting has been an integral part of building our CAR-T community over the years. It has expanded topics, content and speakers to reflect the growth and dynamic nature of this field and has enabled ongoing education, innovation and networking. This is an event I look forward to every year"
>
> **Rizwan Romee**, Associate Professor of Medicine, **Dana Farber Cancer Institute, Harvard Medical School**

> "This is a rapidly evolving field and we have to keep ourselves aware of new data/ideas"
>
> **Elie Haddad**, Professor, Department of Pediatrics, **University of Montreal**

VIEW DAY 1 PLENARY SESSIONS



# CLINICAL MANAGEMENT TRACK

Hear the latest clinical data from seasoned experts leading the way with autologous and allogeneic therapies to make waves in treating patients with solid tumor indications. Optimize the safety profiles of complex cell therapies to improve standard of care and drive successful treatment of vulnerable patients. Challenge the traditional paradigms of cell therapy clinical delivery – can we treat patients earlier in the disease setting with an RNA based cell therapy?

DISCOVERY TRACK
TRANSLATION
EARLY PHASE DEVELOPMENT
MANUFACTURING
CMC/ANALYTICS
LOGISTICS
MARKET ACCESS

## CONFERENCE DAY 1 | SEPTEMBER 20, 2022

- Supercharging Clinical Development of Off-the-Shelf Therapies
- Prioritizing Safety with Improved Toxicity Management

## CONFERENCE DAY 2 | SEPTEMBER 21, 2022

- Simplifying the Patient Journey with Improved Schedule Administration
- Leveraging RNA Technology to Change the Face of Clinical Trial Design
- Exploring Alternative Immunomodulation Strategies

## CONFERENCE DAY 3 | SEPTEMBER 22, 2022

- Exploring Innovations in Delivery & Administration of CAR-T Therapies for Robust Clinical Benefit





REGISTER NOW

## CLINICAL MANAGEMENT TRACK

### MORNING SESSIONS

**Supercharging Clinical Development of Off-the-Shelf Therapies**

**11.15 CLDN18.2-Targeted CAR T-cell Therapy (CT041) in Subjects with Cancers of the Digestive System**

- Claudin18.2 (CLDN18.2) has highly expressed in gastric, pancreatic and other GI cancers
- CT041 were well tolerated in subjects with CLDN18.2-positive digestive system cancers and delivers high response rate and sustained remission in the previously treated subjects with gastric cancer
- CycloCAR technology to co-express IL7+CCL21 may improve the efficacy and allogeneic THANK-uCAR technology could reduce costs and increase affordability in cancer.

**Hong Ma**, Senior Vice President of Clinical Development, **CARsgen**

**11.45 Fulfilling Gene Therapy LTFU Requirements – Operational Considerations**

- Overview of sponsor obligations for fulfilling regulatory requirements with gene therapy designated products
- Implementing within parent studies vs rollover studies
- Rollover protocol considerations for single vs multiple assets
- Leveraging innovative solutions for maximizing data collection for years

**Jim Wise**, Vice President, Head of Center for Immuno-Oncology, Cellular & Gene Therapy, **ICON Global Operations**

**12.15 Developing Next Generation Autologous & Allogeneic TCR T-Cell Therapies in Solid Tumors**

- Learnings from responses across a broad range of solid tumors with autologous SPEAR T-cell therapies (engineered T-cell receptor [TCR] T-cells)
- Considerations for development pathways and commercialization of first- and next-generation SPEAR T-cells in multiple solid tumor indications
- Translational learnings from the clinic that inform development of further next-generation autologous and allogeneic SPEAR T-cells

**Helen Tayton-Martin**, Chief Business Officer, **Adaptimmune**

**12.45 Hosted Lunch**

### POST-LUNCH SESSIONS

**Prioritizing Safety with Improved Toxicity Management**

**13.45 Mitigating Patient Risk Through Safety Profiling**

- Carrying out early assessment of safety profile of new CAR-T therapies
- Characterizing on-tissue off-target reactivity

**Nushmia Khokhar**, Chief Medical Officer, **Umoja Biopharma**

**14.15 Genomic Approaches for Patient Identification & Response Monitoring of Patients Receiving CAR-T Therapy**

- The use of genomic biomarker testing to enable therapeutic identification in patients with cancer
- The emergence of new genomic testing methods for use in CAR-T therapy studies and clinical trials
- An overview of a proof-of-concept study describing measuring longitudinal persistence of a CAR construct and therapeutic response monitoring of DLBCL patients using a novel liquid biopsy assay

**Taylor Jensen**, Vice President, Head of Oncology Science, **LabCorp**

**14.45 Panel Discussion: Developing Safer Cell Therapies for Critically Ill Patients in Need**

- Implementing novel synthetic biology to enhance safety of CAR-T products
- Discussing how to optimize the safety profile of cell therapy products to successfully treat vulnerable patients

**Eric von Hofe**, Senior Advisor, **AffyImmune Therapeutics**

**Harb Wael**, Vice President Medical Affairs, **Syneos Health**

**15.15 Tech Slam**

### AFTERNOON SESSIONS

**Prioritizing Safety with Improved Toxicity Management**

**16.15 Tracking Affinity Tuned CAR-T Cells for Solid Tumors**

- Affinity tuning avoids on-target off-tumor toxicity
- Tracking CAR-T cells helps monitor activity and safety

**Eric von Hofe**, Senior Advisor, **AffyImmune Therapeutics**

**16.45 Understand the Nuances and Avoid Common Challenges in Cell Therapy Trial Execution**

Cell therapy clinical trials have successfully supported regulatory submissions

- The key nuances and challenges to executing clinical trials are known and can be planned for early in development
- The next step in the evolution of cell therapy clinical trial execution is to incorporate new innovations to more efficiently identify sites and patients, increase patient diversity, and reduce site and patient burden.

**Precision for Medicine**

**17.15 Bench to Bedside Translation: Application of Mechanistic Modeling to Cell Therapies**

- Discuss the Quantitative Relationship between CAR-Affinity, Antigen Abundance, Tumor Cell Depletion and CAR-T Cell Expansion
- Understanding the biodistribution of CAR-T cells and Development of a Physiologically Based Pharmacokinetic (PBPK) Model
- Towards Bench-to-Bedside Translation of Cell Therapies using a Multiscale PK-PD Model: Case Study with anti-BCMA CAR-T cell

**18.00 Drinks Reception**

## CLINICAL MANAGEMENT TRACK

### MORNING SESSIONS

**10.30 Tech Slam**

**Simplifying the Patient Journey with Improved Schedule Administration**

**11.30 Navigating High-Risk Patients with Relapsed/ Refractory B-Acute Lymphoblastic Leukemia (r/r B-ALL) Through a CAR-T Therapy for Optimum Outcomes**

- Patients with r/r B-ALL and aggressive clinical course are at high-risk for adverse outcomes in CAR-T clinical trials, and most trials exclude such patients
- Patients can also develop high-risk features post-enrolment while awaiting leukapheresis or infusion
- Successful patient navigation through the phases of CAR-T cell therapy requires skillful clinical management while balancing several competing factors and strategies

**Gaurav Narula**, Professor Pediatric Oncology & Health Sciences, Department of Medical Oncology, **Tata Memorial Center, Homi Bhabha National Institute**

**12.00 Early Detection & Prediction of Febrile Adverse Events using a Wearable Device for High-Frequency Temperature Monitoring in Patients Receiving CAR-T Cell & Other Cellular Therapies**

**Muneesh Tewari**, Professor of Internal Medicine and Biomedical Engineering, Anderson-Sprague Memorial Research Professor, **University of Michigan**

**Leveraging RNA Technology to Change the Face of Clinical Trial Design**

**12.30 The Therapeutic Potential of oRNA**

- LNP-mediated delivery of long, coding RNA has recently been clinically validated for both vaccines and gene editing, and represents a new therapeutic modality
- Developing a class of synthetic, circular RNAs called oRNAs which exhibit significant improvements in production and expression compared to mRNAs
- Combining these oRNAs with delivery solutions beyond traditional hepatotropic LNPs, in particular with those that target cells of the immune system
- Outlining some of the progress we have made with oRNA production, expression and in situ CAR delivery

**Robert Mabry**, Chief Scientific Officer, **Orna Therapeutics**

**13.00 lunch**

### POST-LUNCH SESSIONS

**Leveraging RNA Technology to Change the Face of Clinical Trial Design**

**14.00 RNA Cell Therapies: The Benefits of Being Tame & Temporary**

- A selling-point of conventional, DNA-modified cell therapies (their tendency to divide once administered to a patient) is also a liability that renders them difficult to control, pharmacokinetically unpredictable, and occasionally lethal
- With the advent of longer-lasting mRNAs and the means to transfect billions of cells with these mRNAs, a new class of RNA cell therapy has emerged
- RNA cell therapies have temporary phenotypes with predictable pharmacokinetics and, thus far, a superior safety profile. This makes it possible to develop engineered cell therapies not only for frontline oncology, but also beyond oncology

**Michael Singer**, Chief Scientific Officer, **Cartesian Therapeutics**

**15.00 Panel Discussion: Innovating the Future of Cell Therapy with RNA-Based Approaches**

- Exploring the feasibility of using CAR-T therapies as front-line treatment earlier in the disease setting
- Discussing the complexities of changing treatment paradigms for vulnerable patients

**Robert Mabry**, Chief Scientific Officer, **Orna Therapeutics**

**Michael Singer**, Chief Scientific Officer, **Cartesian Therapeutics**

**15.30 Networking**

### AFTERNOON SESSIONS

**Exploring Alternative Immunomodulation Strategies**

**16.30 Enhancing Persistence & Efficacy of CAR-T Therapies**

- Using adjuvant to enhance performance of current CAR-T therapies
- How these can be quickly translated in the clinical setting for patient benefit

**Rebecca Lim**, Vice President, Scientific Affairs, **Prescient Therapeutics Limited**

**17.30 Eliminating Lymphodepletion (LD) for Allogeneic Cell Therapies: Why & How**

- LD adds to the toxicity of immune cell therapies
- LD impairs the ability to recruit endogenous immune responses generated by cell therapy
- Gene engineering of iPSC-based allogeneic cells may circumvent the need for LD

**Hy Levitsky**, President, Research & Development, **Century Therapeutics**

**18.00 End of Day 2**

## CLINICAL MANAGEMENT TRACK

### MORNING SESSIONS

**Exploring Innovations in Delivery & Administration of CAR-T Therapies for Robust Clinical Benefit**

**11.00 CoupledCAR® Therapy for Patients with Metastatic Colorectal Cancer**

- Novel technological approach using CAR-T therapy to achieve objective responses and clinically meaningful survival in patients with metastatic colorectal cancer
- CoupledCAR is a platform technology that has already been used to benefit patients with different solid tumor indications

**Lucy Lu**, Chief Operating Officer, **Innovative Cellular Therapeutics**

**12.00 Panel Discussion: Improving Relapse Rates for Patients Facing Poor Prognosis**

- Sharing experience of novel strategies, new constructs and differentiated CARs being used to develop efficacious therapies for patients who have exhausted other standard-of-care treatments
- Thinking about how to account for pre-treated patients in clinical trial readouts to showcase true therapeutic success

**Lucy Lu**, Chief Operating Officer, **Innovative Cellular Therapeutics**

**Paul Rennert**, Acting Chief Executive Officer, President, Chief Scientific Officer, **Aleta Biotherapeutics**

**12.30 Lunch & Poster Session**

### POST-LUNCH SESSIONS

**Exploring Innovations in Delivery & Administration of CAR-T Therapies for Robust Clinical Benefit**

**13.30 The Adoptive Cell Therapy Clinical Landscape**

**Sophie Shamsi**, Lead Analyst, **Beacon Targeted Therapies**

**14.00 Our Commitment to Providing Excellence to Cell & Gene Therapy**

This presentation will briefly introduce:

- The trends in cancer cell therapy based on the published data.
- It will mainly focus on Acro's solutions to support cell gene therapy (CGT) at different stages from early drug discovery, manufacture /quality control to preclinical and clinical research.
- It will also introduce Acro's key products, new technology platform and new product pipeline including Star Staining fluorescent conjugation and GMP grade products, etc.

**Teng Peng**, Senior Technique Application Manager, **ACRO Biosystems,Inc.**

**14.30 Characterization of CAR-T Engagers for Diverse Cancers**

- Despite heady successes in B-cell cancers and multiple myeloma, CAR-T therapies have not been as effective in other cancers
- The CAR-T Engager platform is a facile means of improving the functionality of diverse CAR-T cells, irrespective of cell type
- Several examples will be presented, and we will update progress on ALETA-001, soon to enter Phase 1/2 clinical trials

**Paul Rennert**, Acting Chief Executive Officer, President, Chief Scientific Officer, **Aleta Biotherapeutics**

**15.00 Afternoon Break**

**16.00 Closing Plenary Sessions**

> "As we return to in-person conferences, the CAR-TCR Summit provides a highly regarded, cell therapy-focused venue. I expect excellent interactions and discussions during this conference"
>
> **Paul Rennert**, Acting Chief Executive Officer, President, Chief Scientific Officer, **Aleta Biotherapeutics**

> "In the rapidly evolving field of cellular therapy, a meeting focused on the newest advances is very valuable"
>
> **Eric von Hofe**, Senior Advisor, **AffyImmune Therapeutics**

> "This is a very important topic and event. It offers the chance to exchange the latest progress and advances in the field."
>
> **Hong Ma**, Senior Vice President of Clinical Development, **CARsgen**

VIEW DAY 1 PLENARY SESSIONS

# EARLY PHASE DEVELOPMENT

- DISCOVERY
- TRANSLATION
- CLINICAL MANAGEMENT
- MANUFACTURING
- CMC/ANALYTICS
- LOGISTICS
- MARKET ACCESS

For those looking to begin their phase I journey in the clinic, or to maximize the transition from phase I to II, the early phase development track will be a handbook to seamlessly scaling phase operations. Hear from seasoned experts to set up trials for success, create tailored strategies to encourage greater clinical trial participation, and invest in essential infrastructure early to support development of a successful operating model.

## CONFERENCE DAY 1 | SEPTEMBER 20, 2022

- Exploring Phase I/II Product Development
- Meeting Wider Patient Populations

## CONFERENCE DAY 2 | SEPTEMBER 21, 2022

- Prioritizing Safety During Early Development to Create a Smooth Path to Success
- Navigating Through Early Safety Challenges & Concerns for Allogeneic Products

## CONFERENCE DAY 3 | SEPTEMBER 22, 2022

- Establishing Clear Endpoints
- Addressing Phase Dependent Infrastructure Needs

REGISTER BY SEPTEMBER 18 TO SAVE $150

CONTENTS
WELCOME
WHAT'S NEW FOR 2022
SPEAKERS
AGENDA AT A GLANCE
DEEP DIVE DAY WORKSHOPS
DEEP DIVE DAY BOOTCAMPS
FOCUS DAY
DISCOVERY TRACK
TRANSLATION TRACK
CLINICAL MANAGEMENT TRACK
EARLY PHASE DEVELOPMENT TRACK
MANUFACTURING TRACK
CMC/ANALYTICS TRACK
LOGISTICS TRACK
MARKET ACCESS TRACK
PARTNERS
WHO WILL YOU MEET
PRICING & DISCOUNTS

REGISTER NOW

## EARLY PHASE DEVELOPMENT TRACK

### MORNING SESSIONS

**Exploring Phase I/II Product Development**

**11.15 Early Stage Development Strategies Leading to Successful Transition to the Clinic**

- Identification of large sets of human TCRs with high affinity and specificity
- High-throughput TCR screening with low attrition rate
- Thorough safety assessment during early preclinical development to eliminate off-target potential
- Robust screening strategy to identify optimal target patient populations

**Elisa Kieback**, Co-Founder, Chief Technology Officer, **T-Knife Therapeutics**

**11.45 Accelerated Process Development of Engineered Off-the-Shelf Therapeutic T-Cells Using the G-Rex Platform**

- Use of G-Rex6M well plate in process development to help accelerate large characterization studies to screen different conditions on the small scale
- Translation of research protocols to clinical scale production through process continuity between open and closed system G-Rex
- G-Rex scalability and reproducibility enabling predictable scale-up and scale-out as pipeline grows

**Ellie Kamaloo**, Senior Scientist, **Beam Therapeutics**

**12.15 Setting Up a Path for Success to the Clinic by Deploying Fit-for-Growth Capabilities**

- Understanding how early CMC decisions can impact cell therapy manufacturing scalability
- Weighing the pros and cons of developing in house vs outsourcing manufacturing capacity
- Leveraging automation to increase consistency and throughput
- Driving continuous improvement across, processes, materials and equipment

**Bradley Glover**, Chief Technology Officer, **Celularity**

**12.45 Hosted Lunch**

KBI BIOPHARMA | Global QTeIT | TERUMO BLOOD AND CELL TECHNOLOGIES

### POST-LUNCH SESSIONS

**Meeting Wider Patient Populations**

**13.45 Establishing a Patient-Centric Clinical Development Strategy**

- The importance of prioritizing patient needs early in clinical development through commercialization
- The potential of expanding cell therapy to the outpatient setting
- How patient-focus is being considered in next-generation CAR-T development

**Anne Kerber**, Senior Vice President, Cell Therapy Development, **Bristol Myers Squibb**

**11.00 Panel Discussion: Improving Patient Participation in Innovative Clinical Trials**

- How does the industry work with the community to drive the patients towards clinical trials and into that personalized space?
- Ensuring that patients receive the "personalized" touch they deserve
- How can the industry better partner with foundations and organizations that are on the front lines and in the community to provide better education and awareness?
- Review patient enrollment criteria and study design

**Anne Kerber**, Senior Vice President, Cell Therapy Development, **Bristol Myers Squibb**

**Robert Richards**, Administrative Director, Cell Therapy & Transplant, **University of Pennsylvania**

**Kate Rochlin**, Chief Operating Officer, **IN8bio**

**15.15 Tech Slam** FUJIFILM | OVIZIO | TD2 | WellSky

### AFTERNOON SESSIONS

**Meeting Wider Patient Populations**

**16.15 Developing Training Programs to Widen Patient Access to Complex Therapies**

- Collaborating with front line foundations and organizations in the community themselves
- Providing further education to patients/families about safety of clinical trials interest
- Developing reimbursement plans for travel, missed work, childcare, etc. for clinical trial patients

**Robert Richards**, Administrative Director, Cell Therapy & Transplant, **University of Pennsylvania**

**17.15 Building Consistency into Training to Create Infrastructure for a Successful Clinical Trial**

- Building towards phase 2 clinical trials and establish robust manufacturing processes when using a unique cell type
- Case study of using point-of-care manufacturing for phase 1 trials: successes and future considerations
- How do you train and build a workforce when there isn't a big talent pool? Streamlining the training process and equipping workers with the confidence to make critical operator decisions during process development

**Kate Rochlin**, Chief Operating Officer, **IN8bio**

**18.00 Drinks Reception**




REGISTER NOW

## EARLY PHASE DEVELOPMENT TRACK

### MORNING SESSIONS

**Prioritizing Safety During Early Development to Create a Smooth Path to Success**

**10.30 Tech Slam**

**11.30 Combined Molecular & Cellular Tools are Required to Assess Safety of TCR-T Immunotherapies**

- There are no suitable animal models that allow TCR-T immunotherapies to be assessed for safety using *in vivo* models, due to HLA-restriction and species differences in the immunopeptidome of animals and man
- Molecular studies of target antigen expression in healthy tissues, spanning RNA, protein and peptide assessments are needed to judge whether healthy cells could potentially be recognized by TCR-Ts
- Functional studies analyzing both direct recognition and cross-recognition of healthy tissues are needed to establish the safety profile of TCR-Ts. Here comparisons of multiple TCRs in parallel help to select the safest TCR sequences for a given HLA-peptide specificity

**Tristan Holland**, Laboratory Head, TCR Discovery, **Medigene**

**12.00 Antibody Specificity Profiling for IND Using the Membrane Proteome Array**

- IND applications for biotherapeutics require cross-reactivity assessment to prevent adverse events, but ~25% of antibodies in development are polyspecific
- The Membrane Proteome Array is a comprehensive approach to rapidly identify off-target protein-protein interactions
- We will provide an update on the newest additions to this 6,000-protein cell array and the adoption of MPA technology for regulatory filings—including case studies for CAR-T and cell therapy profiling where conventional approaches did not suffice

**Michael Phelan**, Application Scientist, **Integral Molecular**

**12.30 Development of iPSC-Derived CAR-Cell Therapies for the Treatment of Liquid & Solid Tumors**

- Harnessing the power of induced pluripotent stem cells (iPSCs) to develop novel allogeneic CAR-NK and CAR-T cell therapies for cancer
- Multiplex engineering of iPSCs to develop allogeneic immune cells that can persist and safely and effectively mediate anti-tumor immunity
- CAR design strategies that address disease-specific challenges

**Luis Borges**, Chief Scientific Officer, **Century Therapeutics**

**13.00 lunch**

### POST-LUNCH SESSIONS

**Navigating Through Early Safety Challenges & Concerns for Allogeneic Products**

**14.00 Allogeneic vs Autologous Cell Therapies: CAR-T & Beyond**

- How allogeneic T-cell therapies overcome limitations associated with autologous approaches available today
- Potential benefits of allogeneic EBV T-cells to address medical need in EBV driven cancers and auto-immune diseases as well as a platform for allogeneic CAR-T providing safety and efficacy with no need for gene editing TCR or HLA
- Clinical and regulatory experience with Atara's allogeneic T-cell therapies in Phase 2 and Phase 3

**Pascal Touchon**, President & Chief Executive Officer, **Atara Bio**

**14.30 Preclinical Efficacy & Safety Profiling Studies to Support Engineered Cell Therapies**

- Preclinical testing of your cell therapy to support characterization of your lead product or facilitate lead optimization
- In vitro safety assessment against various healthy human tissues using primary and iPSC-derived cells to identify on-target/off-tumor and off-target effects
- Generation of efficacy and safety data packages for the IND submission of your cell therapy

**Gemma Moiset**, Group Leader, **Charles River Laboratories**

**15.00 Panel Discussion: Showcasing Meaningful Safety Endpoints for Faster Approval**

- Sharing experience of novel study design to highlight most relevant safety endpoints
- Understanding latest regulatory guidance on efficacy endpoints for complex therapies
- How best to navigate early conversations with regulatory agencies to inform process development changes

**Luis Borges**, Chief Scientific Officer, **Century Therapeutics**

**Pascal Touchon**, President & Chief Executive Officer, **Atara Bio**

**15.30 Networking**

### AFTERNOON SESSIONS

**Navigating Through Early Safety and Efficacy Challenges for Allogeneic and Autologous Products**

**16.30 TAC-T TCR Technology Leading to New Safe and Effective Cell Therapies in Solid Tumors**

- Innovative Cell therapies capitalizing on TCR to initiate a physiologic immune response which circumvents tonic signaling, associated with past TME penetration, avoid proliferation in normal tissues and persist over time
- Breaking the code of efficacy in Solid Tumors Space
- Fill in therapeutic gaps in areas of unmet medical need with durable efficacy
- Continue the legacy of Cell tx as a one and done approach

**Deyaa Adib**, Chief Medical Officer, **Triumvira Immunologics Inc.**

**17.00 Dose Selection & Dose Optimization in Cellular Oncology Trials: Lessons Learned**

- Revealing Project Optimus and what it means for cellular oncology trials
- Describing preclinical strategies, including animal models, biomarkers and exposure-response relationships, to support initial clinical dosing
- Optimizing starting dose, dose escalation plan and dosing regimen in the clinic and optimizing randomized Phase 2 designs for optimizational dose in registerial trials

**William Kelce**, Executive Director & Early Development Strategy, **OncoBay Clinical**

**Dannelle Palmer**, Chief Operating Officer, **OncoBay Clinical**

**17.30 Allogeneic BCMA CAR-T in Multiple Myeloma**

- Review of BCMA as a target in multiple myeloma
- Overview of clinical data with the first generation BCMA allogeneic CAR-T
- Introduction of TurboCAR technology to increase potency and persistence of BCMA CAR-T

**Erin Karski**, Executive Director, **Allogene Therapeutics**

**18.00 End of Day 2**


REGISTER BY SEPTEMBER 18 TO SAVE $150

CONTENTS
WELCOME
WHAT'S NEW FOR 2022
SPEAKERS
AGENDA AT A GLANCE
DEEP DIVE DAY WORKSHOPS
DEEP DIVE DAY BOOTCAMPS
FOCUS DAY
DISCOVERY TRACK
TRANSLATION TRACK
CLINICAL MANAGEMENT TRACK
EARLY PHASE DEVELOPMENT TRACK
MANUFACTURING TRACK
CMC/ANALYTICS TRACK
LOGISTICS TRACK
MARKET ACCESS TRACK
PARTNERS
WHO WILL YOU MEET
PRICING & DISCOUNTS

REGISTER NOW

## EARLY PHASE DEVELOPMENT TRACK

### MORNING SESSIONS

**Establishing Clear Endpoints**

**11.00 CB-010 – CRISPR Genome-Edited Allogeneic Anti-CD19**

- CAR-T Cell Therapy with a PD-1 Knockout in r/r B-NHL

**Syed Rizvi**, Chief Medical Officer, **Caribou Bio**

**11.30 Rethink RNA-based Delivery and Editing of CAR T Cells: Insights into Lipid Nanoparticle Delivery and Scalable Microfluidic Manufacturing**

- Current gene delivery methods have significant challenges, hindering further innovations in cell therapies.
- Non-viral electroporation method can be harsh on cells, making it difficult to generate quality cells at high yields, whereas conventional viral vector delivery method is expensive and cumbersome to manufacture.
- We would like to present data using a novel proprietary GenVoy-ILM™ lipid nanoparticle platform that overcomes these limitations to enable highly efficient RNA-based gene editing and delivery into human primary T cells while maintaining high cell viability.
- We would also present data of how these particles can be easily scaled across the NanoAssemblr® microfluidic platform from discovery to the clinic.

**Angela Zhang**, Senior Product Manager, **Precision Nanosystems**

**12.00 Audience Discussion: Monitoring Evolution from Academia to Commercialization to Assist Back Translation**

- Developing a strategic mindset to understand key learning curves on the path to clinical development and beyond, and extending these lessons to implement process development changes

**Michael Mehler**, Director, **Immatics**

**Lunch & Poster Session**

### POST-LUNCH SESSIONS

**Addressing Phase Dependent Infrastructure Needs**

**13.30 What Trends are there Within the Preclinical Cell Therapy Space That Will Influence the Next 10 Years of Cell Therapy?**

**Bertie MacArthur**, Sales Manager, **Beacon Targeted Therapies**

**14.00 Building a Commercial-Ready Cell & Gene Therapy Supply Chain: Key Considerations in the Assessment & Integration of cGMP-Compliant Ancillary Materials**

- As the cell and gene therapy industry continues to mature – with a growing number of advanced therapies progressing in the clinic and achieving commercial approval – so too does regulatory oversight and guidance regarding what constitutes a sufficiently robust bill of materials
- With the transition frompreclinical development to late-stage clinical trials, it becomes incumbent upon advanced therapy developers to more thoroughly assess the risk that their starting and ancillary materials present – including the risk that these materials present to the overall product (and ultimately, to patients) as well as challenges that the very sourcing of these products can present as they seek to ensure security of supply
- This presentation will review, from the perspective of a cGMP ancillary material supplier, how advanced therapy developers can mitigate risk by enacting robust supply chain management strategies, assessing critical materials in a phase-appropriate manner, and ultimately, by establishing long-term partnerships to ensure security of supply

**Robert Margolin**, Vice President of Commercial, BioProducts Business, **Akron Bio**

**14.30 Aligning Novel Hybrid Job Roles to Cover the Complexities of Clinical Trial Sites**

**Michael Mehler**, Director, **Immatics**

**15.00 Afternoon Break**

**16.00 Closing Plenary Sessions**

> "As the leader of a company developing innovative, allogeneic cell therapies for a variety of serious conditions, I look forward to sharing my expertise with other attendees as much as I am excited to learning about best practices for developing and commercializing these therapies and ultimately driving the industry forward in addressing unmet medical needs."
>
> **Pascal Touchon**, President & Chief Executive Officer, **Atara Bio**

> "Given our deep history with cell therapy and experience-based knowledge of the intricacies of the field, it's important to join forums where we can meet with other leaders in the space across a wide range of disciplines. The importance of cross-functional collaboration is totally unique in cell therapy compared to other cancer research platforms or modalities, and it's crucial for different functional experts to meet and engage as we strive to transform patients' lives with the promise of cell therapy"
>
> **Anne Kerber**, Senior Vice President, Cell Therapy Development, **Bristol Myers Squibb**

VIEW DAY 1 PLENARY SESSIONS





# MANUFACTURING TRACK

Exploring cutting-edge platforms to automate processes, discussing when and what to automate. Access case study-led sessions across process development, demonstrating innovations scaled lentiviral and non-viral vector manufacturing, debate which process elements to outsource and when, and gain early insights into the allogeneic CAR-NK and stem cell-based manufacturing platforms of the future.

DISCOVERY
TRANSLATION
CLINICAL MANAGEMENT
EARLY PHASE DEVELOPMENT
CMC/ANALYTICS
LOGISTICS
MARKET ACCESS

## CONFERENCE DAY 1 | SEPTEMBER 20, 2022

- Meeting Product Demand with Improved Scale-Up
- Automating the Future of Cell Therapy
- Meeting Product Demand with Improved Scale-Up

## CONFERENCE DAY 2 | SEPTEMBER 21, 2022

- Advancing Non-Viral Gene Modification Strategies
- Managing & Retaining GMP Skilled Workers
- Advancing Manufacturing Turnaround to Increase Patient Access

## CONFERENCE DAY 3 | SEPTEMBER 22, 2022

- Exploring Innovations in Viral Vector Production & Engineering
- Establishing Scalable & Cost-Effective Process Development

## MANUFACTURING TRACK

### MORNING SESSIONS

**Meeting Product Demand with Improved Scale-Up**

**Session Chair: Charles Mooney**, Vice President, Bio-Development Oklahoma Blood Institute, **Blood Centers of America & BCA CT Network**

**11.15 A TCR Approach Towards Addressing Solid Tumors**

- Discussion of the novel TCR2 TRuC platform
- Highlight progress that has been made
- Detail manufacturing enhancements that are being developed

**Peter Olagunju**, Chief Technology Officer, **TCR² Therapeutics**

**11.45 Fast Track to Intelligent Manufacturing**

- Exothera offers a full-service model where it manages all the elements of the product development value chain, from process development to manufacturing
- Several case studies prove the fast process transfer from the flask-based process to single-use fixed-bed scale-X bioreactors
- It is essential to focus on process scalability through comparability of process parameters and critical quality attributes

**Hanna Lesch**, Chief Technology Officer, **Exothera**

**12.15 Subcutaneous Generation of Synthetic Lymph Nodes for the *In Vivo* Production Of CAR-Tank Cells**

- EXUMA Biotech is developing novel viral-engineering technologies and manufacturing processes to enable the *in vivo* generation of CAR-TaNK cells through a subcutaneous injection

**Sid Kerkar**, Vice President, Head of Research & Development, **EXUMA Biotechnology**

**12.45 Hosted Lunch**

KBI BIOPHARMA | Global OTsIT | TERUMO BLOOD AND CELL TECHNOLOGIES

### POST-LUNCH SESSIONS

**Automating the Future of Cell Therapy**

**13.45 Exploring Different Types of Automation & Evolution of Technology**

- Discussing the value proposition for moving toward cell therapy closed system processing
- Increasing quality, throughput and cost with new automation technologies
- Building and optimizing scalable processes and facility design to ensure effective and compliant operations

**Bradley Glover**, Chief Technology Officer, **Celularity**

**14.15 Toward the Nexus of Robotics & Cell Therapy Manufacturing**

- Degrees of automation and the evolution of cell therapy manufacturing
- What is achievable with robotics and innovative technologies? And when?
- Accelerating commercialization with true end-to-end workflow automation

**Fabian Gerlinghaus**, Co-founder & Chief Executive Officer, **Cellares**

**14.45 Panel Discussion: Revolutionizing the Production of Large-Scale Cell Therapy Through Automation**

- How can we really manufacture large quantities of T-cells?
- How can we automate the entire process to reduce the bias between products?
- What is the amount of person-hour reduction achieved with automation?

**Bradley Glover**, Chief Technology Officer, **Cellularity**

**Bruce Levine**, Barbara & Edward Netter Professor in Cancer Gene Therapy, **University of Pennsylvania**

**Nick Ostrout**, Senior Scientific Advisor, **Charles River Laboratories**

**15.15 Tech Slam**

FUJIFILM Irvine Scientific | OVIZIO | TD2 | WellSky

### AFTERNOON SESSIONS

**Meeting Product Demand with Improved Scale-Up**

**16.15 Process Development & Manufacturing of Gene Circuit Engineered Allogeneic CAR-NK Cells**

- Gene circuit is a multi-component genetic construct that programs cells to interact with disease environments using logic to perform desired therapeutic functions
- Gene circuit platform is designed to overcome fundamental disease challenges
- Process development of robust manufacturing of allo-NK-CARs

**Martin Giedlin**, Vice President, Head of Tech Operations, **Senti BioSciences**

**16.45 Process Development & Optimization for Large Scale Cell Manufacturing**

- Efficiency of scale-up process
- Full process from upstream to downstream
- Clinical manufacturing in large scale

**Katsuhiko Nakashima**, Associate Director, MSAT, **Minaris**

**17.15 Establishing an iPSC Platform for T-Cell Therapeutics**

- Developing platforms to direct cell therapy development towards optimal phenotypes
- Introducing iPSCs as a streamlined platform for simplified, scalable manufacturing

**Emily Titus**, Vice President, Process Sciences, **Notch Therapeutics**

**18.00 Drinks Reception**



REGISTER BY SEPTEMBER 18 TO SAVE $150

CONTENTS
WELCOME
WHAT'S NEW FOR 2022
SPEAKERS
AGENDA AT A GLANCE
DEEP DIVE DAY WORKSHOPS
DEEP DIVE DAY BOOTCAMPS
FOCUS DAY
DISCOVERY TRACK
TRANSLATION TRACK
CLINICAL MANAGEMENT TRACK
EARLY PHASE DEVELOPMENT TRACK
MANUFACTURING TRACK
CMC/ANALYTICS TRACK
LOGISTICS TRACK
MARKET ACCESS TRACK
PARTNERS
WHO WILL YOU MEET
PRICING & DISCOUNTS

REGISTER NOW

## MANUFACTURING TRACK

### MORNING SESSIONS

**Advancing Non-Viral Gene Modification Strategies**

**Session Chair: Charles Mooney**, Vice President, Bio-Development Oklahoma Blood Institute, **Blood Centers of America & BCA CT Network**

**11.30 Accelerating Development of Nanoparticle Delivery System for *Ex Vivo* & *In Vivo* Gene Editing**

- Using nanocarriers to deliver mRNA for gene transfection to antigen-specific T-cells
- Exploring development of novel lipid nanoparticles to mediate *ex vivo* mRNA delivery into T-cells for transient CAR expression
- Comparing cell count viability with nanoparticle approach versus electroporation-delivered CAR mRNA

**Birgit Schultes**, Senior Vice President, Cell Therapies, **Intellia Therapeutics**

**12.30 qCART™, A Technology Breakthrough for Virus-Free Multiplex CAR-T Development & Manufacturing**

- qCART™ system shortens the innovation cycle for development of disruptive CAR-Ts to treat solid tumors
- qCART™ rejuvenates the T cells of patients with B cell malignancy
- qCART™ enables high quality multiplex and virus-free CAR-T cell manufacturing in a simple, robust, economic and time-effective fashion

**Karen Wen**, Chief Operating Officer, **GenomeFrontier Therapeutics, Inc.**

**13.00 Lunch & Networking**

### POST-LUNCH SESSIONS

**Managing & Retaining GMP Skilled Workers**

**14.00 Overcoming the Challenges of Cell Therapy Manufacturing: Bridging the Gaps in cGMP Operations for Process & Product Development**

- The process development activities for patient tailored personalized cell therapy products require speed, efficiency while reducing labour and risks
- Process bottle necks are diverse depending on the product and can be handled while opting for right manufacturing platform and reagents and characterization tools
- Cell therapies are "live therapies" with complex product features and viable, reliable supply chain is a bottle neck especially in LMICs
- Shortage of skilled workforce and training programs is daunting for upscale manufacturing in cell therapy.

**Albeena Nisar**, Scientific Officer, CAR-T Cell Therapy Centre & cGMP Cell Therapy Centre, **Tata Memorial Centre Advanced Centre for Treatment, Research & Education in Cancer**

**15.00 Panel Discussion- Forward Engineering Strategies to Future-proof Your Cell Therapy Production Capabilities**

- Control costs and manage risk by collaborating with your IT/Digital team
- Consider how regulatory guidance impacts process development and scale-up
- Build flexibility into your future capacity with a CDMO partnership
- Push the pedal on innovation with the right infrastructure from IT/Digital

**John Lee**, Vice President of Cell Therapy, **Center for Breakthrough Medicines**

**15.30 Tech Slam**

### AFTERNOON SESSIONS

**Advancing Manufacturing Turnaround to Increase Patient Access**

**16.30 Integrating End-to-End Workflows for Improved Efficiency**

- Increasing process robustness by applying early clinical and translational findings to inform process development changes
- Supporting large scale expansion processes to preserve cell product fitness and potency

**Arvind Natarajan**, Senior Vice President, Process & Analytical Process Development, **Iovance Biotherapeutics**

**17.00 Improving T-Cell Therapy Manufacturing Processes With Automation & Scalability**

- The advantages of a closed, automated cell isolation and bead removal system
- What instrumentation can help you scale up to meet the needs that the cell therapy industry requires
- The importance of bioreactor environmental controls

**Evan Zynda**, Senior Scientist, **Thermo Fisher Scientific**

**17.30 Performance Enhancement: Pushing the Design Envelope in CAR-T Cell Manufacturing**

- First science, then design, then engineering, repeat
- Disseminate globally for patient access

**Bruce Levine**, Barbara & Edward Netter Professor in Cancer Gene Therapy, **University of Pennsylvania**

**18.00 End of Day 2**


REGISTER BY SEPTEMBER 18 TO SAVE $150

CONTENTS
WELCOME
WHAT'S NEW FOR 2022
SPEAKERS
AGENDA AT A GLANCE
DEEP DIVE DAY WORKSHOPS
DEEP DIVE DAY BOOTCAMPS
FOCUS DAY
DISCOVERY TRACK
TRANSLATION TRACK
CLINICAL MANAGEMENT TRACK
EARLY PHASE DEVELOPMENT TRACK
MANUFACTURING TRACK
CMC/ANALYTICS TRACK
LOGISTICS TRACK
MARKET ACCESS TRACK
PARTNERS
WHO WILL YOU MEET
PRICING & DISCOUNTS

REGISTER NOW

## MANUFACTURING TRACK

### MORNING SESSIONS

**Exploring Innovations in Viral Vector Production & Engineering**

**Session Chair: Charles Mooney**, Vice President, Bio-Development Oklahoma Blood Institute, **Blood Centers of America & BCA CT Network**

**11.00 Lentivirus Engineering for Antigen Identification & Cell Type Specificity**

- We have developed a novel lentivirus pseudotyping strategy that enables improved cell type specificity
- This technology enables both antigen identification via library-based approaches and delivery of therapeutic cargoes

**Michael Birnbaum**, Associate Professor, Department of Biological Engineering, **Massachusetts Institute of Technology**

**12.00 Panel Discussion: Industry-Academic-Biomanufacturing partnerships**

- What does the future hold?

**Eytan Abraham**, Vice President and Business Head, Cell, Gene and Nucleic Acids; **Resilience**

**Shishir Gadam**, Chief Technology Officer, **Syncopation Life Sciences**

**Bruce Thompson**, Vice President and Technical Lead, **Cell Therapy; Resilience**

**Jason Bock**, Chief Executive Officer, **Cell Therapy Manufacturing Center (CTMC)**

**12.30 Lunch & Poster Session**

### POST-LUNCH SESSIONS

**Establishing Scalable & Cost-Effective Process Development**

**13.30 *In Vivo* Reprogramming Using Retroviral-Based IV-CAR-X to Improve Patient Outcomes & Access**

- Reprogramming a range of proliferating innate and adaptive immune effector cell subsets to generate more potent and durable immune responses against cancer
- Increasing probability of success by leveraging clinically proven technologies and scaled manufacturing processes

**Cory Bentley**, Co-Founder & Senior Vice President, Research & Development, **Abintus Bio**

**14.00 Modular Technology to Manufacture Cell, Gene & Exosome Therapies**

**Jenna Balestrini**, Head of Strategy and Business Development for Bioprocessing, **Draper**

**14.30 Allogeneic CAR-T Cells Genome-Edited with chRDNA Technology Exhibit Increased Potency & Persistence in Preclinical Models**

- Caribou biosciences has developed a scalable manufacturing process for efficiently editing healthy donor T-cells using chRDNA technology.
- We are developing allogeneic therapies with multiple molecular strategies to increase CAR-T cell potency and persistence.

**Justin Skoble**, Vice President of Technical Operations, **Caribou Biosciences**

**15.00 Afternoon Break**

**16.00 Closing Plenary Sessions**

> "This meeting is an exciting opportunity to collaborate with all stakeholders in the field of CAR-T cell therapy and it hosts the best of industry and academia across the globe."
>
> **Albeena Nisar**, Scientific Officer, CAR-T Cell Therapy Centre & cGMP Cell Therapy Centre, **Tata Memorial Centre Advanced Centre for Treatment, Research & Education in Cancer**

> "It's an exciting time in immunology and cell therapies - I can't wait to share our progress and to see advances both in industry and academia from groups around the world."
>
> **Michael Birnbaum**, Associate Professor, Department of Biological Engineering, **Massachusetts Institute of Technology**


REGISTER BY SEPTEMBER 18 TO SAVE $150

CONTENTS
WELCOME
WHAT'S NEW FOR 2022
SPEAKERS
AGENDA AT A GLANCE
DEEP DIVE DAY WORKSHOPS
DEEP DIVE DAY BOOTCAMPS
FOCUS DAY
DISCOVERY TRACK
TRANSLATION TRACK
CLINICAL MANAGEMENT TRACK
EARLY PHASE DEVELOPMENT TRACK
MANUFACTURING TRACK
CMC/ANALYTICS TRACK
LOGISTICS TRACK
MARKET ACCESS TRACK
PARTNERS
WHO WILL YOU MEET
PRICING & DISCOUNTS

REGISTER NOW

NEW

# CMC/ ANALYTICS TRACK

- DISCOVERY
- TRANSLATION
- CLINICAL MANAGEMENT
- EARLY PHASE DEVELOPMENT
- MANUFACTURING
- LOGISTICS
- MARKET ACCESS



For those looking to develop gold standards for CMC to drive development of safe and high quality products, look no further than the brand new CMC/Analytics track! Explore innovative technologies for product characterization, cutting edge analytical tools, streamlined control strategies and integrated QC across the entire development chain to meet the latest regulatory expectations.

## CONFERENCE DAY 1 | SEPTEMBER 20, 2022

- Enhancing Product Characterization to Determine Product Attribute
- Determining Potency with Validated Functional Assays
- Developing a High-Quality Product to Meet Regulatory Expectations

## CONFERENCE DAY 2 | SEPTEMBER 21, 2022

- Managing Heterogeneity of Cell Starting Sources
- Maintaining Product Quality During End-to-End Development

## CONFERENCE DAY 3 | SEPTEMBER 22, 2022

- Streamlining Release Testing



REGISTER NOW

## CMC/ANALYTICS TRACK

### MORNING SESSIONS

**Enhancing Product Characterization to Determine Product Attribute**

**11.15 Determining Product Characterization for Use in Comparability Studies**

- Explore the use of high content flow cytometry and mass cytometry to better understand product attributes
- Establishing a set criteria to decide how much characterization is useful to include and in which cases

**11.45 Towards Quantitative & Standardized Flow Cytometric Assays**

- Flow cytometric assays have been used to measure critical quality attributes of cell and gene therapy products
- The lack of reproducibility and comparability of assay results across different flow cytometer platforms remains a significant challenge for the field
- NIST Flow Cytometry Standards Consortium is established to develop measurement solutions, standards and best practices to accelerate the translation, manufacturing and approval of regenerative medicine and advanced therapy products

**Lili Wang**, Senior Research Scientist, **National Institute of Standards & Technology**

**12.15 Clinical Sample Testing: From Specimen Receipt to Data & All the Qualifications in Between**

- Triumvira initiated its first clinical trial in September 2021. An aggressive post-infusion specimen sampling program meant building infrastructure to support receipt, accessioning, processing and testing of clinical samples
- Database creation and management, flow charts, qualified assays and data analysis will be discussed

**Michael Marit**, Associate Director, MSAT, **Triumvira Immunologics**

**12.45 Hosted Lunch**

KBI BIOPHARMA | Global QTeIT | TERUMO BLOOD AND CELL TECHNOLOGIES

### POST-LUNCH SESSIONS

**Determining Potency with Validated Functional Assays**

**13.45 Levelling the Playing Field with LLV Analytics**

- The importance of internal viral analytics comparing multiple vendors
- Strategies for deploying viral analytics
- Case study

**14.15 Developing Bioluminescent Assay Platforms for Phase-Appropriate CAR-T Potency Assessment**

- Discussing the challenges of developing and incorporating MoA-based CAR-T potency assays
- Describing the development of homogenous LUMIT cytokine immune assays for fast and easy CAR-T characterization
- Describing the capability of HiBiT target cell killing assay to quantitatively measure CAR-T cytotoxicity, specificity and functional kinetics, and its potential to support GMP QC release testing for late stage clinical and commercial products

**Julia Gilden**, Senior Scientist, **Promega**

**14.45 Panel Discussion: Driving Potency Assay Development for Optimal Reproducibility**

- Developing clinically relevant potency assays for control of product quality and consistency
- Developing a robust potency assay to produce quick turnaround times in a QC environment

**Michael Lehmicke**, Vice President, Science & Industry Affairs, **The Alliance for Regenerative Medicine**

**15.15 Tech Slam** FUJIFILM Value from Innovation | IrisScientific | OVIZIO | TD2 Precision Oncology | WellSky

### AFTERNOON SESSIONS

**Developing a High-Quality Product to Meet Regulatory Expectations**

**16.15 To Build or Not to Build, Navigating Cell & Gene Therapy Commercialization**

- Current and Future CGT Manufacturing Overview from Therapeutic Developers' Perspective
- Recent Trends in CGT CMC and What's Next
- Build vs Outsource Considerations

**Matthew Hewitt**, Executive Director - Scientific Solutions, Cell & Gene Therapy, **Charles River Laboratories**

**16.45 Regulatory CMC Considerations in the Development of CAR-T Products**

- Aspects of CMC that are unique to CAR-T products
- CMC regulatory focus points and strategy
- CMC case studies with CAR-T submissions

**Kent Amsberry**, Director, Advanced Therapy Product Development Regulatory Sciences, Specialty Solutions, **Cardinal Health**

**17.15 Archetypes of CMC Excellence**

- Recent regulatory CMC guidance
- The A-Cell case study

**Michael Lehmicke**, Vice President, Science & Industry Affairs, **The Alliance for Regenerative Medicine**

**18.00 Drinks Reception**

## CMC/ANALYTICS TRACK

### MORNING SESSIONS

**10.30 Tech Slam**

**Managing Heterogeneity of Cell Starting Sources**

**11.30 Clinical Manufacture of iPSC-Derived CAR-NK & CAR-T Cells for Off-the-Shelf Cancer Immunotherapy**

- Concurrent reprogramming and genetic engineering enables the generation of clonal, engineered master iPSC lines that represent a uniform and renewable cell source for clinical manufacture of CAR-NK and CAR-T cells
- A defined, cGMP-compliant, scalable directed differentiation platform results in thousands of clonally derived doses of off-the-shelf CAR-NK and CAR-T products to support early and late stage clinical development

**Raedun Clarke**, Senior Director, Process Development, **Fate Therapeutics**

**12.30 Industrialization of CAR-T Therapies Autologous vs Allogeneic: Common & Uncommon Hurdles**

- Overcoming donor-patient variability for development of a safe allogeneic or autologous product
- Novel analytical methods to identify cell numbers that you can get out of the patient, how healthy those cells are, and what their phenotype is
- Understanding how to determine patient cell numbers when the analytical process is developed based on healthy individuals

**Karen Walker**, Chief Technology Officer, **Kyverna Therapeutics**

**13.00 lunch**

### POST-LUNCH SESSIONS

**Maintaining Product Quality During End-to-End Development**

**14.00 Determining Critical Quality Attributes of Final Product**

- Interdependence between the end product CQAs and bioprocess platforms
- Which bioprocess parameters affect CQAs
- Concomitant optimization and control of end product CQAs and bioprocess platforms

**Isabelle Rivière**, Director, Cell Therapy & Cell Engineering Laboratory, **Memorial Sloan Kettering Cancer Center**

**14.30 For Patients, the Status Quo Isn't Good Enough**

- As an industry we need to refocus our attention on the metric that matters: how many patients have we successfully treated with cell and gene therapies? Not enough, we still have cures for cancer and rare diseases that most patients can't get access to
- We envision a future where biology, engineering and data sciences combine into a scalable process with discovery and manufacturing platforms to increase throughput, improve quality and reduce costs
- Prioritizing flexible and scalable manufacturing early in development is critical to creating widespread patient access to cell and gene therapies

**Jason Foster**, Chief Executive Officer, **Ori Biotech**

**15.00 Panel Discussion: Accelerating Commercialization of Cell Therapy Products with a Phase Appropriate CMC Strategy**

- How does process validation and analytical method validation overlap in later stages?
- What does it mean to have a phase appropriate method development/validation and why do we need it?
- What are the agency requirements/expectations vs what can be delivered?

**Karen Walker**, Chief Technology Officer, **Kyverna Therapeutics**
**Isabelle Rivière**, Director, Cell Therapy & Cell Engineering Laboratory, **Memorial Sloan Kettering Cancer Center**
**Raedun Clarke**, Senior Director, Process Development, **Fate Therapeutics**
**Giuliana Vallanti**,Head, Development and Global Cell &Gene Therapy R&D , **AGC Biologics**

**15.30 Networking**

### AFTERNOON SESSIONS

**Maintaining Product Quality During End-to-End Development**

**16.30 Defining Critical Quality Attributes (CQAs) of Genetically Engineered Cell Therapy Products**

- Overview of CQAs of CAR and TCR products in the field
- How CQAs can be tailored to specific product in hand
- Development and validation of assays, establishing acceptance criteria
- CQAs as parameters to understand the clinical effect of CAR and TCR products

**Lavakumar (Kumar) Karyampudi**, Director of Cell Therapies Facility, **Moffitt Cancer Center**

**17.30 Defining Process Controls to Drive Consistency & Quality of Product**

**Anthony Colenburg**, Director of Quality, **Adicet Bio**

**18.00 End of Day 2**


REGISTER BY SEPTEMBER 18 TO SAVE $150

CONTENTS
WELCOME
WHAT'S NEW FOR 2022
SPEAKERS
AGENDA AT A GLANCE
DEEP DIVE DAY WORKSHOPS
DEEP DIVE DAY BOOTCAMPS
FOCUS DAY
DISCOVERY TRACK
TRANSLATION TRACK
CLINICAL MANAGEMENT TRACK
EARLY PHASE DEVELOPMENT TRACK
MANUFACTURING TRACK
CMC/ANALYTICS TRACK
LOGISTICS TRACK
MARKET ACCESS TRACK
PARTNERS
WHO WILL YOU MEET
PRICING & DISCOUNTS

REGISTER NOW

## CMC/ANALYTICS TRACK

### MORNING SESSIONS

**Streamlining Release Testing**

**11.00 Analytical Assays for CAR-T therapies – Streamlining Strategy from IND to Clinical**

- Define CQAs at various stages of the process
- Rigorous method development to better represent product quality and safety
- Product lifecycle management: monitoring controls and consistency of analytical methods
- Technical, quality, and regulatory considerations for lot release and stability testing

**Aish Sathyanarayan**, Senior Scientist, Process Analytics, **Poseida Therapeutics**

**11.30 Implementing a 1-hour Mycoplasma Test for Immune-Effector Cells**

- Addressing the current challenges faced in product release
- Benefits of an ultra-rapid and simplified assay to face scarcity of highly skilled workforce
- Validation approach for multiple products

**Zankar Desai**, Cell Therapy Testing Lab Manager, **Dana-Farber Cancer Institute**

**12.00 Panel Discussion: Accelerating the Release Timelines with Improved Safety Testing**

- Revealing insights into the latest technologies available to generate greater understanding of the cell product and better release criteria
- Exploiting how to release both allogeneic and autologous products as fast as possible for patients in need
- Examining the rate limiting step of safety testing in the release timelines

**Antoine Suteau**, Senior Quality Assurance Manager, **Novartis**

**Aish Sathyanarayan**, Senior Scientist, Process Analytics, **Poseida Therapeutics**

**12.30 Lunch & Poster Session**

### POST-LUNCH SESSIONS

**Streamlining Release Testing**

**13.30 Improving Rapid Product Release Methods to Decrease Vein-to-Vein Time**

- Streamlining operations from start to finish - establish a value stream
- Keeping up to date with technology advancement and alternatives to compendia methods
- Performing interim release to decrease shipping time impact after release

**Antoine Suteau**, Senior Quality Assurance Manager, **Novartis**

**14.30 Audience Discussion: Advancing Development of Release Testing Specification to Reduce Time to Administration**

- Speeding up the process for QC to release product
- Overcoming the burden of release with patient-knowledge based specifications

**15.00 Afternoon Break**

> "Genetically engineered cell therapy products are at their primetime in the treatment of cancer patients. The CAR-TCR Summit brings together the best talent in this field and facilitates exchange of views/ideas related to ongoing research. This is really key to driving the exemplary immunotherapy options towards success."
>
> **Lavakumar (Kumar) Karyampudi**, Director of Cell Therapies Facility, **Moffitt Cancer Center**

> "Sharing knowledge and concepts ensures that companies can share best practices and continue to improve quality and safety to benefit patients. This meeting is in alignment with this belief."
>
> **Antoine Suteau**, Senior Quality Assurance Manager, **Novartis**

VIEW DAY 1 PLENARY SESSIONS



# LOGISTICS TRACK

- DISCOVERY
- TRANSLATION
- CLINICAL MANAGEMENT
- EARLY PHASE DEVELOPMENT
- MANUFACTURING
- CMC/ANALYTICS
- MARKET ACCESS

Establish robust digital supply chains to track product location and performance of autologous and allogeneic cell products and scale supply to meet demand. Join industry experts to advance cryopreservation, achieve consistency at apheresis and preserve the chain of identity with an integrated and unified data management approach.

## CONFERENCE DAY 1 | SEPTEMBER 20, 2022

- Advancing Digital Traceability for Improved Product Tracking
- Navigating Through Complex Supply Chains with Greater Collaboration & Integration

## CONFERENCE DAY 2 | SEPTEMBER 21, 2022

- Advancing Supply Chain Coordination
- Enhancing Security & Control of Products with Clear COI
- Optimizing Apheresis, Cryopreservation & Transfusion Protocols for Greater Product Quality

## CONFERENCE DAY 3 | SEPTEMBER 22, 2022

- Setting Up a Supply Chain to Support Phase Appropriate Growth & Scalability

## LOGISTICS TRACK

### MORNING SESSIONS

**Advancing Digital Traceability for Improved Product Tracking**

**11.15 Paving the Way for Success by Establishing Early Digital Solutions Along the Supply Chain**

- Establishing foundational opportunities along the supply chain to implement digital solutions
- Simple "Pre-ERP" SAAS options to move forward with to advance maturity

**Bob Amareld**, Head of Supply Chain, **Precision Biosciences**

**11.45 Digitizing the CAR-T/TCR Manufacturing Process - An Overview & Best Practice**

- Specific challenges in the digitization of CGT/ATMP processes
- A best practice approach to electronic batch record for CAR-T/TCR
- An overview of digital data management for CAR-T/TCR processes

**Judith Koliwe**r, Principal Consultant Cell & Gene Therapy, **Körber Pharma Software**

**12.15 Transitioning to Electronic Systems: Electronic Batch Record, LIMS & System Integration**

- Discussion on transition of paper systems to electronic 21 CFR part 11 compliant systems including successes and challenges along the way
- Electronic system validation strategy and data integrity audits

**Michelle Andraza**, Senior Director, Global Quality Assurance, **Exuma Biotech**

**12.45 Hosted Lunch**

KBI BIOPHARMA | Global QTeIT | TERUMO BLOOD AND CELL TECHNOLOGIES

### POST-LUNCH SESSIONS

**Navigating Through Complex Supply Chains with Greater Collaboration & Integration**

**13.45 Teaching an Elephant to Surf - Overcoming Big Pharma Cell & Gene Therapy Industrialization Challenges for Value Chain Orchestration & Exceptions Management**

- The wave: Introduction of the evolving Roche/Genentech cell & gene therapy portfolio as an example for a diverse/multi-modality portfolio
- Understanding the challenge: discussion of the key challenges and complexity associated with a multi-modality portfolio for a big pharma company
- Getting in shape and learning the technique: building business capabilities for value chain orchestration
- Getting the right board: Introduction of our approach for an O&EM platform which allows for a multi-modality application at scale
- Getting into water: outlook and discussion of the benefits of the approach (de-risk investments, automation, etc.)

**Christian Fuchs**, Head of Orchestration & Exceptions Management Cell & Gene Therapy, **Roche/Genentech**

**14.15 Establishing a Platform Strategy for Cell & Gene Therapy Supply Chains**

- With the number of commercialized advanced therapies being launched, integrating supply chain activities is increasingly important to effectively support the following:
  - Unified data streams
  - Integration of physical material management
  - Optimization of supply chain activities to improve overall COG's

**Mark Sawicki**, President & Chief Executive Officer, **Cryoport**

**14.45 Panel Discussion: Supercharging Seamless Delivery of Complex Cell Therapies with Integrated Systems**

- Overcoming logistical challenges associated with a variety of databases and data management systems across the supply chain through a unified solution

**Bob Amareld**, Head of Supply Chain, **Precision Biosciences**
**Christian Fuchs**, Head of Orchestration & Exceptions Management Cell & Gene Therapy, **Roche/Genentech**
**Michelle Andraza**, Senior Director, Global Quality Assuran, **Exuma Biotech**
**Andrea Zobel**, Senior Director, Personalized Supply Chain, **World Courier**

**15.15 Tech Slam** FUJIFILM Irvine Scientific | OVIZIO | TD2 | WellSky

### AFTERNOON SESSIONS

**Navigating Through Complex Supply Chains with Greater Collaboration & Integration**

**16.15 Vein-to-Vein: Supplier Management for Autologous CAR-Ts**

**Ed Armstrong**, Senior Director Quality, **Mustang Bio**

**16.45 Planning Cell & Gene Supply Chain Logistics - Clinical Through Commercial Speed to Scale – Leveraging Experience, New Ideas & Technology**

- The escalating pace of clinical trial to commercialization is forcing a new level of planning and innovation as cell and gene therapy companies quickly move through early-stage clinical trials to full-scale global commercialization
- Common missteps and challenges in the COVID age, and how some cell and gene therapy supply chain organizations are mitigating risk through careful advance planning

**Kent Thorup**, Regional Vice President, **QuickSTAT Global Life Science Logistics**

**17.15 Addressing Disruption to Global Supply Chain in Real-Time Amidst a Post-Covid World**

- Maintaining freedom of movement of raw materials and cell sample both in-country and across borders in the midst of changing restrictions
- Ensuring consistent apheresis and patient delivery in the midst of pandemic

**18.00 Drinks Reception**

# LOGISTICS TRACK

## MORNING SESSIONS

**10.30 Tech Slam**

**Advancing Supply Chain Coordination**

**11.30 Supply Chain Commercialization of Autologous Therapies**

- Order to cash readiness
- Patient scheduling and orchestration
- Utilization of digital systems

**David Kim**, Head of Supply Chain, **Arcellx**

**12.00 The Supply Chain Ripple Effect: How Adopting a Commercial Mentality from the Start Mitigates Risk & Accelerates Development**

- When it comes to your supply chain for cell sourcing, you must embrace a commercial mindset whatever phase of development your cell or gene therapy is in. And that means starting with the end goal in mind and working in reverse
- With the anticipated trajectory of cell and gene therapy development and approvals, you need a resilient cell sourcing infrastructure from the start, including suppliers that can meet your long-term demand

**Joy Aho**, Director, Product Management, **Be The Match BioTherapies**

**12.30 How to Leverage Key Supplier Relationships for Better End-to-End Control via Collaboration in Strategic Sourcing & Clinical Supply Planning**

- 2-3 case study examples of how the strategic sourcing and planning functions at Precision BioSciences collaborated to improve relationships with external couriers, and how we apply the same concepts to other critical suppliers and service providers end-to-end (e.g raw material suppliers, 3rd party test labs, CDMO, etc.)
- Highlight the tools and concepts we used in our success and the importance of having supplier segmentation in place to support supplier management efforts and drive collaboration with key suppliers
- Strategic sourcing and planning functions working closely together to mitigate 3rd party risk (e.g suppliers, couriers) in the supply chain

**Ryan Phillips**, Strategic Sourcing Manager, **Precision BioSciences**
**Justin Dunlevy**, Clinical Supply Chain Manager, **Precision BioSciences**

**13.00 Lunch**

## POST-LUNCH SESSIONS

**Enhancing Security & Control of Products with Clear COI**

**14.00 Ensuring Data Integrity & Security During Preclinical Development to Maintain Quality**

- Ensuring secure movement across the entire supply chain using a universal and traceable system

**Anthony Colenburg**, Director of Quality, **Adicet Bio**

**15.00 Panel Discussion: Optimizing & Standardizing Supply Chain Design to Improve Product Quality**

- Establishing industry-wide guidelines for complex cell therapy supply chains
- Discussing how to advance the supply chain process to best support optimal manufacturing
- Working with centers of excellence to understand how best to maintain product quality with novel assessment forms in the clinical supply chain

**Anthony Colenburg**, Director of Quality, **Adicet Bio**

**Ryan Phillips**, Strategic Sourcing Manager, **Precision BioSciences**

**David Kim**, Head of Supply Chain, **Arcellx**

**15.30 Networking**

## AFTERNOON SESSIONS

**Optimizing Apheresis, Cryopreservation & Transfusion Protocols for Greater Product Quality**

**16.30 Cryopreservation & Formulation Considerations for Best-in-Practice Cell Therapy Manufacturing**

- Effect of formulation and freezing parameters on cell therapy product stability
- Impact of unintentional warming of frozen cells
- Cold chain considerations to minimize impact to post-thaw cellular attributes

**Tracey Turner**, Scientist, Formulation & Cryobiology in the Cell Therapy Development Organization, **Bristol Myers Squibb**

**17.00 Apheresis Capacity Across the US to Support Autologous Therapies – Current Landscape & Expansion to Meet Industry Growth**

- Commercialization of autologous cellular therapies requires a robust, distributed apheresis network with adequate capacity and the ability to scale rapidly
- Clinical trial collections in support of autologous cellular therapies often rely on in-house apheresis resources at large medical institutions, which are typically constrained in terms of apheresis capacity and focused on apheresis to support their own patients
- Neutral, third-party platforms for apheresis services to support commercial roll-out and growth supports the ability for patients to access therapy close to home

**Melissa Sebok**, Executive Director – Product, Client & Business Development, Direct Patient Care & Emerging Offerings, **American Red Cross Biomedical Services**

**17.30 Audience Discussion - Utilizing a Large Supply Chain Distribution Network for Cryopreservation**

- Exploring novel cryopreservation processing techniques for long term storage of cells to enable wide scale/international on demand shipping
- Maintaining biological activity and potency after cryopreservation and streamlining global distribution

**18.00 End of Day 2**

REGISTER BY SEPTEMBER 18 TO SAVE $150

CONTENTS
WELCOME
WHAT'S NEW FOR 2022
SPEAKERS
AGENDA AT A GLANCE
DEEP DIVE DAY WORKSHOPS
DEEP DIVE DAY BOOTCAMPS
FOCUS DAY
DISCOVERY TRACK
TRANSLATION TRACK
CLINICAL MANAGEMENT TRACK
EARLY PHASE DEVELOPMENT TRACK
MANUFACTURING TRACK
CMC/ANALYTICS TRACK
LOGISTICS TRACK
MARKET ACCESS TRACK
PARTNERS
WHO WILL YOU MEET
PRICING & DISCOUNTS

REGISTER NOW

## LOGISTICS TRACK

### MORNING SESSIONS

**Setting Up a Supply Chain to Support Phase Appropriate Growth & Scalability**

**11.00 Building a Patient-Centric Operational Network Between a Cell Therapy Sponsor & Clinical Site**

- Bridging site-facing cross-functional gaps:
  - Clinical Operations
  - Supply Chain
  - Medical Affairs
- Overcoming operational challenges of autologous cell therapies

**Michael Mehler**, Director, Global Site Operations, **Immatics**

**11.30 Setting Up Future-Proof Supply Chain Operations for Cell & Gene Therapies**

- Understand key parameters that impact supply chain ops for cell and gene therapies
- Share learnings from the industry
- Discuss core capabilities and investments for setting up cell and gene therapy platform operations
- Explore key considerations for setting up the organization

**Oliver Eitelwein**, Partner, Health & Life Sciences, **Oliver Wyman**

**12.00 Panel Discussion: Maintaining Supply Chain Growth to Keep Pace with Product Supply for Patients**

- Building and sustaining strong partnerships between manufacturing and supply chain organizations to allow for smooth product delivery
- Discussing 'best practice' in supply chain and logistics, from clinical integration, digital systems, cold chain supply, vendor and partnerships management, and patient operations organizations
- Exploring streamlined supply chain models that offer both flexibility and reliability

**Michael Mehler**, Director, Global Site Operations, **Immatics**

**Aaron Vernon**, Vice President, Technical Operations, **TCR² Therapeutics**

**Chris Wiwi**, Vice President Technical Operations, **Mnemo Therapeutics**

**12.30 Lunch & Poster Session**

### POST-LUNCH SESSIONS

**Setting up a Supply chain to Support Phase Appropriate Growth & Scalability**

**13.30 Building for Cell Therapy Supply Capabilities for Near & Long-Term Needs**

- Cell therapy supply chains are notoriously complex and expensive to change
- Companies need to integrate financial, program and product planning to enable good decision making across the supply chain
- They must also develop strategies that enable resolution of long-term issues (COGS, reliability, reduced risk) while enabling phase appropriate capacity and capabilities based on business environment constraints

**Aaron Vernon**, Vice President, Technical Operations, **TCR² Therapeutics**

**14.00 Addressing Industry Challenges in Cell & Gene Therapy Supply Chain Through Global, Integrated Solutions**

- Key considerations when building a flexible and scalable supply chain, including sample collection, ultra-cold & cryogenic storage, packaging/labeling, transportation & distribution, chain of custody & identity, etc.
- Differences in strategy with autologous vs. allogeneic therapies
- Impact of regional regulatory requirements for CGT products and importance of global distribution partner to maximize patient access
- Lessons learned/best practices to mitigate risk in your supply chain and accelerate the path from clinic to commercialization
- Benefits of leveraging an integrated services model across entire manufacturing lifecycle and supply chain

**Susan Li**, Director of Customer Solutions, BioServices & Specialty Logistics, **Thermo Fisher Scientific**

**14.30 Optimizing Cell Product Characteristics & Manufacturing / Supply Chain in a Phase Appropriate Manner**

- Optimization of cell product characteristics for improved clinical performance
- Cell process and product characterization as tools to enable accelerated development of cell therapy candidates
- Impact of manufacturing and supply chain decisions in early development on commercial success

**Chris Wiwi**, Vice President Technical Operations, **Mnemo Therapeutics**

**15.00 Afternoon Break**

> "The CAR-T industry is still nascent and every biotech company is paving their own way. It's critical that biotechs learn from each other and network to overcome challenges that stand in the way of providing patients the access to our next generation cancer therapies. Specifically to help overcome challenges of supply chain risk."
>
> **Ryan Phillips**, Strategic Sourcing Manager, **Precision BioSciences**

> "The value in taking part in the meeting for me is to share the learnings and challenges we faced when building this platform for our manufacturing process and sharing these learnings will greatly help others as the industry moves more and more towards electronic systems."
>
> **Michelle Andraza**, Director, **Exuma Biotech**

VIEW DAY 1 PLENARY SESSIONS



# MARKET ACCESS

- DISCOVERY
- TRANSLATION
- CLINICAL MANAGEMENT
- EARLY PHASE DEVELOPMENT
- MANUFACTURING
- CMC/ANALYTICS
- LOGISTICS

Discuss the market potential, integrate commercial readiness from early phases, anticipate the commercial hurdles to enhance the therapeutic experience for patients and physicians. Explore novel pricing and reimbursement models to improve access and education and learn how to market ground-breaking therapies from the industry experts who are delivering them at scale.

## CONFERENCE DAY 1 | SEPTEMBER 20, 2022

- Remodeling Pricing & Reimbursement Structures for Greater Affordability
- Demonstrating Long Term Value & Reducing Post Approval Changes

## CONFERENCE DAY 2 | SEPTEMBER 21, 2022

- Creating a Patient-Centric Framework to Accelerate Access
- Shining a Spotlight on Patient Perspectives & Experiences with Approved Cell Therapies
- Preparing for Commercialization During Product Conception

## CONFERENCE DAY 3 | SEPTEMBER 22, 2022

- Gaining Insight into Payer Perspective
- Leveraging Past Experience to Build the Path to Commercial Success

REGISTER BY SEPTEMBER 18 TO SAVE $150

CONTENTS
WELCOME
WHAT'S NEW FOR 2022
SPEAKERS
AGENDA AT A GLANCE
DEEP DIVE DAY WORKSHOPS
DEEP DIVE DAY BOOTCAMPS
FOCUS DAY
DISCOVERY TRACK
TRANSLATION TRACK
CLINICAL MANAGEMENT TRACK
EARLY PHASE DEVELOPMENT TRACK
MANUFACTURING TRACK
CMC/ANALYTICS TRACK
LOGISTICS TRACK
MARKET ACCESS TRACK
PARTNERS
WHO WILL YOU MEET
PRICING & DISCOUNTS

REGISTER NOW

## MARKET ACCESS TRACK

### MORNING SESSIONS

**Remodeling Pricing & Reimbursement Structures for Greater Affordability**

**11.15 Can Precision Reimbursement Innovation Match Precision Oncology Therapeutic Advances?**

- Patient access to targeted, durable therapies can be inhibited by reimbursement models designed decades ago
- New Precision Reimbursement models from performance-based purchasing arrangements to warranties and risk sharing could improve access and financial sustainability
- Might the future bring further payment innovations such as subscription models and indication-based pricing?

**Mark Trusheim**, Strategic Director, **NEWDIGS**

**11.45 Securing A Win-Win: Achieve Full Product Commercial Potential By Optimizing Your Supply Chain Strategy**

- Breaking down barriers between R&D and commercial teams in early strategic planning
- Ensuring synergies between patient journey and product journey
- Leading with data integration to generate end-to-end data insights

**Lung-I Cheng**, Vice President, Cell and Gene Therapy, **AmerisourceBergen**

**12.15 Increasing Patient Access to Cell Therapy with Novel Pricing Reimbursement Models**

- What role does reimbursement play in securing access to novel cell therapies?
- What innovative payment paradigms have facilitated access to cell therapies?
- What opportunities and challenges do novel payment models (e.g. outcomes-based arrangements) face?
- How can we level innovative thinking to ensure broad future patient access to cell therapies?

**Laura Okpala**, Senior Director, Reimbursement Policy, **Gilead**

**12.45 Hosted Lunch**

KBI BIOPHARMA | Global QTeIT | TERUMO BLOOD AND CELL TECHNOLOGIES

### POST-LUNCH SESSIONS

**Demonstrating Long Term Value & Reducing Post Approval Changes**

**13.45 Reimagining Value Creation for Innovation with Allogeneic Cell Therapies in Ultra Rare Disease to Benefit Patients, Payers & Small Biotech Companies**

- Small biotech organizations take on high risk and investment to move innovation forward in ultra-rare disease states where the unmet need for highly vulnerable patients can be impacted with treatments with curative intent with limited resources and small economies of scale
- Critical affordability strategies for pre-approval engagement to partner for expedited access and negotiate appropriate reimbursement while understanding the lack of revenue streams at baseline
- The value to payers to engage with small manufacturers differently with unique strategies including clinical trial-based PA's/Medical Policies, innovative distribution models and site of care management to account for initial up-front investment

**Jodie Wehling**, Vice President, Market Access, Payer Marketing & Strategic Accounts, **Atara Bio**

**14.15 Relaunching the Concorde: Learnings from Provider and Patient Experiences and Lessons for the Future**

- Insights from more than 100 healthcare providers and patients experienced with cell therapies
- Opportunities for differentiation and leadership
- Commercialization implications for existing and new cell and gene therapy manufacturers

**Maria Whitman,** Global Head of Pharmaceuticals and Biotech, **ZS**
**Sankalp Sethi,** Principal – Cell and Gene Therapy, **ZS**

**14.45 Panel Discussion: The Price is Right – Determining Therapeutic Value in the Real World**

- Discussing how to support patient access to novel and complex cell therapies with meaningful evidence packages
- Exploring how to facilitate sustainable commercialization of therapies now considered 'curative'

**Jodie Wehling**, Vice President, Market Access, Payer Marketing & Strategic Accounts, **Atara Bio**
**Laura Okpala**, Senior Director, Reimbursement Policy, **Gilead**
**Mark Trusheim**, Strategic Director, **Massachusetts Institute of Technology, NEWDIGS**

**15.15 Tech Slam** FUJIFILM | OVIZIO | TD2 | WellSky

### AFTERNOON SESSIONS

**Demonstrating Long Term Value & Reducing Post-Approval Changes**

**16.15 Accelerate Licensing of Cell & Gene Therapies with Early Attention to Detailed Product Characterization, Preclinical Studies & Enhanced Manufacturing**

- Manufacturing platforms
- Product characterization from cell banking to commercial scale manufacturing
- Defining comprehensive preclinical in vitro/in vivo approaches

**Shirley Bartido**, Director, Global Regulatory Affairs Cell Therapy Oncology, **Takeda Pharmaceutical Company**

**17.15 Audience Discussion: Supplementing Clinical Trial Design with Real World Data**

- Utilizing real world data to drive filing, registration and approval
- Showcasing long term follow up clinical data with the real world parameters to highlight value of the cell therapy product
- Establishing support for patients to access newly commercialized products

**18.00 Drinks Reception**




REGISTER NOW

## MARKET ACCESS TRACK

### MORNING SESSIONS

**10.30 Tech Slam**

**Creating a Patient-Centric Framework to Accelerate Access**

**11.30 Developing Next Generation Programmed T-Cell Therapies**

- Key features of a successful CAR-T cell therapy
- Advanced T-cell programming
- Broad pipeline of next generation programs

**Brent Rice**, Senior Vice President, Chief Commercial Officer, **Autolus**

**12.30 Roundtable Discussion: Autologous Vs Allogeneic – How is Each Approach Evolving to Improve Patient Access?**

- While marketed autologous CAR-T therapies are transformational in their respective diseases, a variety of factors have limited utilization to a subset of the eligible population
- In concept, allogeneic approaches have the potential to address many (but not all) the factors that have limited uptake to date, but work remains to see this through and position this approach as an option vs autologous and other modalities
- At the same time, autologous therapies are advancing which address many (but not all) of the limiting factors. However, it remains unclear if improvements that are envisioned will be sufficient to address the challenges or if new challenges will arise

**Michael DeRidder**, Senior Vice President, Corporate Strategy & New Product Planning, **Catamaran Bio**

**13.00 Lunch**

### POST-LUNCH SESSIONS

**Shining a Spotlight on Patient Perspectives & Experiences with Approved Cell Therapies**

**14.00 Celebrating 10 Years of CAR-T Cell Therapy**

- The story of Emily's journey to CAR-T cell therapy
- Update on Emily 10 years cancer free and the significance of that milestone as a cure
- Update on how the Emily Whitehead Foundation helps patients and families find similar success

**Tom Whitehead**, Co-founder, **Emily Whitehead Foundation**

**15.00 Panel Discussion: Setting a Path for Sustainable Reimbursement Frameworks with Broader Value Assessment**

- Where to now? Securing the future of cell therapy with greater market education
- Discussing how to establish stronger measures of therapeutic value, beyond pivotal trials, at a patient level
- Exploring perspectives of both patients and payer and how to align the different stakeholder viewpoints with commercial development

**Brent Rice**, Senior Vice President, Chief Commercial Officer, **Autolus**

**Michael DeRidder**, Senior Vice President, Corporate Strategy & New Product Planning, **Catamaran Bio**

**15.30 Networking**

### AFTERNOON SESSIONS

**Preparing for Commercialization During Product Conception**

**16.30 Commercial Considerations in Building a Pipeline**

- Why it is critical to consider commercialization when building a pipeline
- What are some of the key elements to consider early on

**Jennifer Chow**, Chief Executive Officer & Managing Director, **Chimeric Therapeutics**

**17.30 Early Cell Therapy Commercial Development Considerations**

- Commercial leaders must consider future Clinical, Operations and Economic profiles of new cellular therapies.

**Steve Gavel**, Vice President Global Commercial Development, **Legend Biotech**

**18.00 End of Day 2**

## MARKET ACCESS TRACK

### MORNING SESSIONS

**Gaining Insight into Payer Perspective**

**11.00 Could Innovative Payment Models Also Generate Evidence?**

- Performance-based contracts and other payment innovations mitigate the financial risks of performance uncertainty by tracking patient outcomes
- Could the results from such payment innovations remove the uncertainties and enable the return of simpler payment models?
- Might the clinical data from such contracts even be used to refine clinical regimens to improve future patient outcomes?

**Mark Trusheim**, Strategic Director, **NEWDIGS**

**12.00 Panel Discussion: How to Succeed in a Competitive Cell Therapy Landscape**

- How pharma can make smart decisions unique to cell therapy opportunities
- Tailoring your business development framework for cell therapies
- How market access as a function can help drive decision making across the organization

**Steve Gavel,** Vice President Global Commercial Development, **Legend Biotech**

**Candice Lo**, Global Value & Access Lead, Cell Therapies, **Takeda Oncology**

**Maria Whitman**, Global Head of Pharmaceuticals & Biotechnology, **ZS**

**12.30 Lunch & Poster Session**

### POST-LUNCH SESSIONS

**Leveraging Past Experience to Build the Path to Commercial Success**

**13.30 Unlocking the Promise of Cell Therapy**

**Bryan Campbell**, Senior Vice President, Cell Therapy Franchise Lead, **Bristol Myers Squibb**

**14.30 Audience Discussion: Revealing Industry Insights on the Requirements Needed to Accelerate a Product Through to Market**

- With an ever increasingly competitive and populated landscape, how do you define a niche for your commercial product?
- Discussing support available to small biotechs in bringing novel and complex cell therapies to the commercial market
- Future strategies to support scaled commercialization to stimulate competition price reduction

**15.00 Afternoon Break**

> "It feels like we've reached an inflection point in CAR-T cell therapy, as leaders are learning how to maximize the potential of first-generation approaches while we simultaneously innovate for the future. Conferences and cross-functional dialogue are vital to connect leaders in cell therapy, enabling us to collaborate and share learnings with one another, all united toward the common goal of delivering life-changing treatments to patients."
>
> **Lynelle Hoch**, Senior Vice President, Cell Therapy Franchise Lead, **Bristol Myers Squibb**

> "Looking forward to sharing latest trends and insights with cellular therapies and garnering a variety of perspectives on the challenges and solutions to cell therapies."
>
> **Michael DeRidder**, Senior Vice President, Corporate Strategy & New Product Planning, **Catamaran Bio**

# Why Partner

Your ultimate platform to network and connect with leaders in the exploding CAR-TCR world:

- Join the global VPs, Directors, and C-Level executives who are searching for the right partners to support pipeline development in 2022 and beyond

- Expand your network to new horizons and touch base with established industry pioneers bringing novel CAR-NK, gamma delta, allogeneic and iPSC constructs to the clinic

- Take advantage of in-person networking, personal introductions, and tailored partnership opportunities to drive your brand in 2022

## Partnership Support

**Pre-Event Consultation –** Working together to create a clear plan and strategy to ensure you maximize the opportunity

**Customer Profiling –** Understand who to prioritise at the event based on who's actively asking for support

**Networking Support –** Collaborative approach to help facilitate introductions with your top prospects

## Get In Touch

sponsor@hansonwade.com

Bashir Langhi

Jonathan Kilby-Philips

## Attendance by Company Type

**Drug Developer: 43%**

**Equipment & Service Provider: 26%**

**Healthcare Provider: 13%**

**Research Institute: 6%**

**Other: 12%**

* Based on previous year's attendance

## Attendance by Seniority



**C-Level: 15%**

**VP: 18%**

**Global head/ Head of: 10%**

**Director: 27%**

**Manager: 15%**

**Scientist: 11%**

**Professor: 4%**

## Industry Stages

**Key opinion leaders who have been part of the journey for over a decade**

Kite Pharma · Penn · Novartis

**Companies in mid-stage or early stage trials with novel platform tech**

Cellectis · Adaptimmune · Atara Bio

**Emerging novel technology companies who are using new approaches**

CurrusBiologics · IMMTUNE THERAPIES

**Companies with candidates in late stage clinical trials with a BCMA or alternative targeted CAR or TCR**

Bellicum · Bristol Myers Squibb · 2seventybio

**Non T-cell companies who span the clinical development phases**

carisma THERAPEUTICS · Fate THERAPEUTICS · TC BIOPHARM

**1000 Attendees**

**200 Speakers**

**300 Companies**



REGISTER NOW

# Partners

## Lead Partner

Lonza
Cell & Gene

## Expertise Partners

ALLCELLS® A Discovery Life Sciences™ Company
EVERSANA™
PRECISION ADVANCE the cell & gene therapy collective™
TERUMO BLOOD AND CELL TECHNOLOGIES
ThermoFisher SCIENTIFIC

## Industry Partners

A2 BIO
SERVIER

# Partners

## Program Partners

## Hosting Partners

## Exhibition Partners

**Want to See Your Logo Here? Get in Touch: Sponsor@hansonwade.com**

# READY TO REGISTER?

## Team Discounts*

- 3 passes - 10% Discount
- 5 passes - 15% Discount
- 8 passes - 20% Discount

Group discounts only apply when booking a full 3-day conference package, and cannot be used in conjunction with any other discount (including academic rates). Group discounts can still be applied to earlybird savings. For more information on group rates and eligibility criteria, please email info@hansonwade.com or visit the website. Full T&Cs apply.

## Secure Your Place Now

| Drug Developer Pricing* | Register by Sunday, September 18 | On the Door Rate |
|---|---|---|
| Conference + Workshop Day OR Bootcamp OR Focus Day | $5,848 **(Save $150)** | $5,998 |
| Conference Only | $4,449 **(Save $150)** | $4,649 |
| Bootcamp Day Only | $1,499 | |
| Investors Roundtable | $100 | |

*Must be from a biotech or pharma company that is currently and publicly developing an in-house CAR-T or TCR therapy to be eligible for this price

*Registration is now closed for companies **not** publicly developing a cellular therapy. Visit the website to register your interest for 2023. www.car-tcr-summit.com/take-part/register/

* Reduced rates are available for **full-time academics** and **small biotechs with less than 50 employees**. Please visit our website for more information.

# VENUE

## Hynes Convention Center

**Hynes Convention Center, 900 Boylston St, Boston, MA 02115 United States**

https://www.signatureboston.com/hynes/

**3 Easy Ways To Book** www.car-tcr-summit.com/take-part/register/ Email: register@hansonwade.com Tel: +1 617 455 4188

TERMS & CONDITIONS

**Full payment is due on registration. Cancellation and Substitution Policy:** Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

**Changes to Conference & Agenda:** Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

**Data Protection:** The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH



REGISTER BY SEPTEMBER 18 TO SAVE $150

CONTENTS
WELCOME
WHAT'S NEW FOR 2022
SPEAKERS
AGENDA AT A GLANCE
DEEP DIVE DAY WORKSHOPS
DEEP DIVE DAY BOOTCAMPS
FOCUS DAY
DISCOVERY TRACK
TRANSLATION TRACK
CLINICAL MANAGEMENT TRACK
EARLY PHASE DEVELOPMENT TRACK
MANUFACTURING TRACK
CMC/ANALYTICS TRACK
LOGISTICS TRACK
MARKET ACCESS TRACK
PARTNERS
WHO WILL YOU MEET
PRICING & DISCOUNTS

REGISTER NOW